WO2010084152A1 - Novel bicyclic antibiotics - Google Patents
Novel bicyclic antibiotics Download PDFInfo
- Publication number
- WO2010084152A1 WO2010084152A1 PCT/EP2010/050684 EP2010050684W WO2010084152A1 WO 2010084152 A1 WO2010084152 A1 WO 2010084152A1 EP 2010050684 W EP2010050684 W EP 2010050684W WO 2010084152 A1 WO2010084152 A1 WO 2010084152A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- mmol
- methoxy
- formula
- piperidin
- Prior art date
Links
- 0 CCC*C(*=*C1=*C)=*C1=*C(*)=* Chemical compound CCC*C(*=*C1=*C)=*C1=*C(*)=* 0.000 description 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present invention relates to antibacterial compounds of a formula:
- Xl, XZ, X3; X4, X5, X6, and X7 each independently of the others, represent nitrogen or CR2 wherein at least one of all groups Xl, X2, X3; X4, X5, X6, and X7 but not more than two of either X4, X5 and X6 or Xl, X2, X3 and X7 represent nitrogen and wherein Rl and R2 are selected from hydrogen and certain substituents which substituents also include more complex molecular side chains.
- Xl represents CR2 wherein R2 represents such a molecular side chain like e.g. corresponding quinolines, quinoxalines or naphthyridines, which are known from WO2002/072572, WO2004/035569, WO2006/002047, WO2006/014580, WO2006/021448, WO2006/032466, and WO2007/086016.
- WO2006/021448 discloses antibacterial compounds with the general structure
- XZ, X3, X4, X5, X6 and X7 independently represent N or CR2, wherein R2 represents hydrogen or a substituent; SP represents linear two-atomic spacer group like in particular -NHCO-; -CH 2 CO-; -COCH 2 -, -CH 2 SO 2 -; -NH SO 2 -; -CH 2 CH(OH)-; -CH 2 CH 2 -; -CH(OH) CH 2 -; -CONH-; -CH 2 N(C i-C 4 alkyl)-; -CH 2 O- or -CH 2 S- and
- R represents a group selected from C6-C8cycloalkylene groups; saturated and unsaturated 4 to 8-membered heterocyclodiyl with 1, 2 or 3 heteroatoms selected from nitrogen and oxygen, which group is unsubstituted or substituted.
- the numerous exemplified compounds are said to exhibit a MIC ( ⁇ g/ml) against at least one of the following microorganisms: Acinetobacter baumannii; Enterobacter cloacae; Escherichia coli; Klebsiella pneumoniae; Proteus mirabilis; Pseudomonas aeruginosa; Stenotrophomonas maltophilia; Staphylococcus aureus; Enterococcus faecalis; Staphylococcus epidermidis; Streptococcus pneumoniae and Enterococcus faecium of less or equal to 8 ⁇ g/ml.
- the present invention relates to such antibacterial compounds of novel chemical structure.
- it relates to compounds of formula (I)
- X2 represents C-H, C-(Cl-C ⁇ alkyl), C-(Cl-C ⁇ alkoxy), C-halogen, C-COOH;
- X5 represents C-H or C-(Cl-C ⁇ alkyl), C-halogen;
- Rl and R2 independently of one another, represent hydrogen or a substituent selected from hydroxy, halogen, carboxy, amino, Cl-C6alkylamino, di(Cl-C6alkyl)amino, mercapto (SH), cyano, nitro, Cl-C6alkyl, Cl-C6alkoxy, Cl-C6alkylthio, Cl-C6alkylaminocarbonyloxy, C2-C6alkenyl,
- Al represents a divalent group of one of the formulae
- A2 is a group selected from C3-C8cycloalkylene; saturated and unsaturated 4 to 8- membered heterocyclodiyl with 1 , 2 or 3 heteroatoms selected from nitrogen, oxygen and sulphur, which group A2 is unsubstituted or substituted;
- R4 represents hydrogen or Cl-C4alkyl;
- the compounds of the invention show good activity against pathogenic bacteria, in particular against at least one of the following Gram-positive pathogenic bacteria like staphylococci, streptococci and Gram-negative bacteria such as for example Escherichia coli, as shown in the Examples. Furthermore they are active against enterococci, and Haemophilus influenzae.
- the antibacterial activity found is particularly surprising because it has been found that the compounds of WO2006/021448 loose their antibacterial activity when the side chain is shifted from the position disclosed in WO2006/021448 to that of the present invention as shown in the following table.
- Cl-C6alkyl preferably refers to saturated, straight-chain or branched hydrocarbon groups having from 1 to 6 carbon atoms like, for example methyl, ethyl, propyl, ⁇ o-propyl, ⁇ -butyl, ⁇ o-butyl, tert-hv ⁇ y ⁇ , ⁇ -pentyl, ⁇ -hexyl or 2,2-dimethylbutyl.
- C1-C4 alkyl is generally preferred.
- composed expressions like e.g.
- Cl-C6alkoxy Cl- C ⁇ alkylamino or di(Cl-C6alkyl)amino, aralkyl or heteroaralkyl or the like
- Cl-C6alkyl is understood in the same way.
- Alkyl groups may also be further substituted by carboxy, amino, mono- or di(Cl-C4alkyl)amino, halogeno, e.g.
- C2-C6alkenyl and “C2-C6alkynyl” preferably refer to at least partially unsaturated, straight-chain or branched hydrocarbon groups that contain from 2 to 6 carbon atoms, preferably from 2 to 4 carbon atoms like, for example, ethenyl, allyl, propargyl, isoprenyl or hex-2-enyl group.
- alkenyl groups have one or two (especially one) double bond(s) and alkynyl groups have one or two (especially one) triple bond(s). Groups having one double and one triple bond are also covered like e.g. pent-3-en-l-yne.
- halogeno e.g. by fluorine, chlorine, bromine or iodine, cyano, hydroxy, mercapto, Cl-C4alkoxy, Cl-
- C3-C6heteroalkyl preferably refers to an alkyl, alkenyl or alkynyl group (for example heteroalkenyl, heteroalkynyl) in which one or more (preferably 1, 2 or 3) carbon atoms have been replaced each independently of the others by an oxygen, nitrogen, silicon or sulphur atom, preferably an oxygen, sulphur or nitrogen atom.
- Specific examples of heteroalkyl groups are methoxymethyl, ethoxymethyl, methoxyethyl, methylaminomethyl, ethylaminomethyl, diisopropyl-aminoethyl, enol ether, dimethylaminomethyl, dimethylaminoethyl.
- the alkyl part(s) of "C3-C6heteroalkyl” can be further substituted as defined for Cl-C6alkyl.
- C3-C8cycloalkylene preferably refers to a bivalent saturated or partially unsaturated (for example a cyclic group having one, two or more double bonds, such as a cycloalkenylene group), cyclic group containing from 3 to 8 carbon atoms, especially 3, 4, 5, 6 or 7, preferably 5 or 6 ring carbon atoms.
- cycloalkylene refers furthermore to groups in which one or more hydrogen atoms have been replaced each independently of the others by carboxy, amino, mono- or di(Cl-C4alkyl)amino, halogeno, e.g.
- cycloalkylene groups are cyclobutylene, cyclopentylene, cyclohexylene, cyclopentenylene and cyclohexadienylene.
- heterocyclodiyl as used herein preferably refers to a saturated or unsaturated bivalent 4 to 8-membered cyclic group as defined above in connection with the definition of cycloalkylene (including divalent heteroaromatic groups), in which one or more (preferably 1, 2 or 3) ring carbon atoms have been replaced each independently of the other by an oxygen, nitrogen, silicon, or sulphur atom, preferably by an oxygen, sulphur or most preferably nitrogen atom.
- heterocyclodiyl refers furthermore to groups in which one or more hydrogen atoms have been replaced each independently of the others by carboxy, amino, mono- or di(Cl-C4alkyl)amino, halogeno, e.g.
- heterocyclodiyl groups in particular of A2 in the meaning "heterocyclodiyl” are hydroxy, Cl-C4alkyl and carboxy.
- Suitable examples of heterocyclodiyl groups include piperidin-diyl, piperazin-diyl, morpholin-diyl, pyrrolidin-diyl, tetrahydro-thiophenyl-diyl, tetrahydropyran-diyl, tetrahydrofuran-diyl or 2-pyrazolin-diyl. Particularly preferred are saturated or unsaturated
- aryl as used herein preferably refers to an aromatic group that contains one or more rings and from 6 to 14 ring carbon atoms, preferably from 6 to 10 (especially 6) ring carbon atoms.
- the expression aryl preferably refers furthermore to such groups in which one or more hydrogen atoms have been replaced each independently of the others by alkyl, fluorine, chlorine, bromine or iodine atoms or by carboxy, alkoxy, mono- or di(Cl- C4alkyl)amino, OH, NH 2 , cyano Or NO 2 groups.
- Examples are phenyl, 4-methyl-phenyl, A- tert-butyl-phenyl; 3-fluoro-4-methyl-phenyl, 3-fluoro-4-(trifluoromethyl)-phenyl; naphthyl, biphenyl, 2-fluorophenyl, anilinyl, 3-nitro-phenyl or 4-hydroxyphenyl.
- heteroaryl as used herein preferably refers to an aromatic group that contains one or more rings and from 5 to 14 ring atoms, preferably from 5 to 10 (especially 5, 6, 8, 9 or 10) ring atoms, and contains one or more (preferably 1, 2, 3 or 4) oxygen, nitrogen or sulphur ring atoms, preferably oxygen, sulfur or nitrogen atoms.
- heteroaryl preferably refers furthermore to groups in which one or more hydrogen atoms have been replaced each independently of the others by fluorine, chlorine, bromine or iodine atoms or by carboxy, alkyl, alkoxy, mono- or di(Cl-C4alkyl)amino, OH, mercapto, NH 2 , cyano, NO 2 or unsubstituted heteroaryl groups.
- Examples are pyridyl, imidazolyl, thiophenyl, thieno[3,2-b]thiophenyl, benzo[b]thiophenyl, furanyl, benzofuranyl, imidazolyl, benzimidazolyl, pyrrolyl, indolyl, oxazolyl, isoxazolyl, indazolyl, indolyl, pyridazinyl, quinolinyl, purinyl, carbazolyl, acridinyl, pyrimidyl, pyrazolyl and isoquinolinyl groups.
- cycloalkane preferably refers to a saturated or partially unsaturated cyclic group which contains one or more, e.g. one or two rings and from 3 to 14 ring carbon atoms, preferably from 3 to 10, most preferably 5 or 6 ring carbon atoms.
- Further specific examples of cycloalkane groups are a cyclopropane, cyclobutane, cyclopentane, cyclohexane, cyclopentene, cyclohexadiene.
- heterocycloalkane as used herein preferably refers to cycloalkane groups as defined above in which one or more, preferably 1 , 2 or 3 ring carbon atoms have been replaced each independently of the others by an oxygen, nitrogen, silicon or sulphur atom, preferably an oxygen, sulphur or nitrogen atom.
- a heterocycloalkane group has preferably 1 or 2 ring(s) containing from 3 to 10, most preferably 5 or 6 ring atoms.
- Examples are a piperidine, piperazine, morpholine, pyrrolidine, thiomorpholine, tetrahydrothiophene, [l,4]dioxane, tetrahydropyrane, tetrahydrofurane or pyrazoline and also lactams, lactones, cyclic imides and cyclic anhydrides, like e.g., morpholin-3-one or thiomorpholin-3-one.
- halogen refers to fluorine, chlorine bromine and iodine.
- Certain compounds of formula (I) may contain one, two or more centres of chirality.
- the present invention therefore includes both all pure enantiomers and all pure diastereoisomers and also mixtures thereof in any mixing ratio.
- the present invention moreover also includes all cis/ trans-isomers of the compounds of the general formula (I) and mixtures thereof.
- the present invention moreover includes all tautomeric forms of the compounds of formula (I).
- X3 and Xl represent a nitrogen atom
- X3 and X6 represent a nitrogen atom
- Those groups X which do not represent a nitrogen atom are preferably a CH group.
- Rl is selected from halogen and Cl-C6alkoxy, preferably Cl-C4alkoxy, in particular from fluoro and methoxy.
- A2 represents a group selected from C5-C6cycloalkylene and saturated or unsaturated 4 to 6-membered heterocyclodiyl with one or two nitrogen atoms as the heteroatom(s), in particular unsubstitued C5-C6cycloalkylene and saturated 4 to 6- membered heterocyclodiyl with one nitrogen atom as the heteroatom, in particular the compounds of formula (I) wherein A2 is selected from:
- the group G in formula (I) represents preferably a C6-C10aryl group which is unsubstituted or further substituted by one or more halogen atoms, in particular chloro or fluoro, and/or straight-chain or branched Cl-C4alkyl groups which may optionally be further substituted by fluoro, like e.g.
- phenyl group or a 5- or 6- membered heteroaryl group comprising heteroatoms selected from oxygen, sulphur or nitrogen, which phenyl group or 5- or 6-membered heteroaryl group are unsubstituted or substituted by one or more halogen atoms, in particular chloro or fluoro, and/or straight- chain or branched Cl-C4alkyl groups which may optionally be further substituted by fluoro, like e.g.
- group G is the following groups:
- R2 is selected from hydrogen, hydroxy, halogen, Cl-C6alkyl, Cl-C6alkoxy, carboxy;
- A2 is unsubstituted or substituted with a group selected from hydroxy, Cl-C4alkyl and carboxy;
- Examples of pharmacologically acceptable salts of the compounds of formula (I) are salts of physiologically acceptable mineral acids, such as hydrochloric acid, sulphuric acid and phosphoric acid, or salts of organic acids, such as methane- sulphonic acid, p- toluenesulphonic acid, lactic acid, acetic acid, trifluoroacetic acid, citric acid, succinic acid, fumaric acid, maleic acid and salicylic acid.
- physiologically acceptable mineral acids such as hydrochloric acid, sulphuric acid and phosphoric acid
- organic acids such as methane- sulphonic acid, p- toluenesulphonic acid, lactic acid, acetic acid, trifluoroacetic acid, citric acid, succinic acid, fumaric acid, maleic acid and salicylic acid.
- pharmacologically acceptable salts of the compounds of formula (I) are alkali metal and alkaline earth metal salts such as, for example, sodium, potassium, lithium, calcium or magnesium salts, ammonium salts or salts of organic bases such as, for example, methylamine, dimethylamine, triethylamine, piperidine, ethylenediamine, lysine, choline hydroxide, meglumine, morpholine or arginine salts.
- alkali metal and alkaline earth metal salts such as, for example, sodium, potassium, lithium, calcium or magnesium salts
- ammonium salts or salts of organic bases such as, for example, methylamine, dimethylamine, triethylamine, piperidine, ethylenediamine, lysine, choline hydroxide, meglumine, morpholine or arginine salts.
- the compounds of formula (I) may also be solvated, especially hydrated. Solvation and hydration may take place, for example, during the preparation process.
- compositions according to the present invention can be prepared e.g. by one of the processes (a), (b) or (c) described below; followed, if necessary, by: removing any protecting groups; forming a pharmaceutically acceptable salt; forming a pharmaceutically acceptable solvate or hydrate.
- Y is a leaving group like methylsulfonyl, tolylsulfonyl, trifluoromethylsulfonyl or halogen
- A3b is absent or represents Cl-C3alkylene, Cl-C3alkenylene, or a group selected from -CH 2 NH-, -CH 2 O-, and -CH 2 S-, said group being linked to G via the nitrogen, oxygen or sulfur atom,
- LO may require appropriate activation to allow a reaction of compounds of formulae II and III as described in more detail below.
- Xl, X2, X3, X4, X5, X6, Rl, A2, R4, m and n are as in formula I
- L2 is a halogen atom, SH, OH or a group OSO 2 R in which R is CH 3 , CF 3 , or tolyl
- Ll and L2 are selected such that the reaction results in the formation of a compound of formula VIII wherein A is as defined above,
- E is -A3-G (A3 and G being as defined in formula I) or an amino protecting group, such as allyloxycarbonyl, benzyloxycarbonyl, 9-fluorenylmethylcarbonyl tert-butoxycarbonyl or benzyl, and when E is a protecting group, said protecting group is removed and the deprotected intermediate is reacted with a compound of formula III
- G-A3b-L0 (III): wherein G, A3b and LO are as defined above.
- LO may, in certain cases, require appropriate activation to allow connection of the deprotected intermediate and the compound of formula (III).
- Xl, X2, X3, X4, X5, X6, Rl, R4, m and n are as in formula I,
- A2 is an unsubstituted or substituted, saturated or unsaturated 4 to 8-membered heterocyclodiyl group with 1 , 2 or 3 heteroatoms selected from nitrogen, oxygen and sulphur, at least one of which heteroatoms is nitrogen atom and
- H [ N] represents a hydrogen atom bound to bound to a nitrogen ring atom of A2, L3 is -CHO, and
- E is an amino protecting group or a group of formula -A3 -G, wherein
- A3 and G have the same meaning as in formula I, and wherein when E is a protecting group, said protecting group is removed and the deprotected intermediate is reacted with a compound of formula III G-A3b-L0 (III): wherein G, A3 and LO are as defined above
- LO may, in certain cases, require appropriate activation to allow connection of the deprotected intermediate and the compound of formula (III).
- the protecting groups may be removed at any convenient stage in the synthesis using conventional techniques well known in the art, or they may be removed during a later reaction step or work-up.
- PGl is a protecting group (such as allyloxycarbonyl (Alloc), benzyloxycarbonyl, 9-fluorenylmethylcarbonyl (Fmoc), tert-butoxycarbonyl (Boc) or benzyl), Ll and L2 are halogen, in particular Br, Cl, or OH, and the other symbols have the same meanings as previously described.
- protecting group such as allyloxycarbonyl (Alloc), benzyloxycarbonyl, 9-fluorenylmethylcarbonyl (Fmoc), tert-butoxycarbonyl (Boc) or benzyl
- Ll and L2 are halogen, in particular Br, Cl, or OH, and the other symbols have the same meanings as previously described.
- Compounds of formula V-I are usually obtained by reacting the corresponding free amine with allyl, fluorenylmethyl or benzyl chloroformate or with di tert-butyl dicarbonate in presence of a base such as sodium hydroxide, sodium hydrogencarbonate, triethylamine, A- dimethylaminopyridine or imidazole. They can also be protected as N-benzyl derivatives by reaction with benzyl bromide or chloride in presence of a base such as sodium carbonate or triethylamine. Alternatively, N-benzyl derivatives can be obtained through reductive amination in presence of benzaldehyde. Further strategies to introduce other amine protecting groups have been described in Protective Groups in Organic Synthesis, 3 rd Edition, by T. W. Greene and P.G.M. Wuts, published by John Wiley & Sons, 1999.
- An alternative route to form compounds of formula VIII-I consists of reacting compounds of formula V-I wherein L2 is -OH with compounds of formula IV-I for which Ll is a hydroxy group, which needs to be activated prior to the reaction as described below or a halogen atom in presence of an inorganic base such as sodium hydride or the like in a solvent such as dichloromethane or N,N-dimethylformamide at a temperature ranging between -20
- Activation of the hydroxy group of compounds of formula V-I wherein Ll is - OH as for example a mesylate, a tosylate or a triflate can be achieved by reacting the compound of formula V-I wherein Ll is -OH with methanesulfonyl chloride or methanesulfonic anhydride, /?-toluenesulfonyl chloride, trifluoromethanesulfonyl chloride or trifluoromethanesulfonic anhydride, respectively, in presence of a base such as triethylamine or the like in a dry aprotic solvent such as pyridine, acetonitrile, tetrahydrofuran or dichloromethane between -30 0 C and 60 0 C.
- a base such as triethylamine or the like
- a dry aprotic solvent such as pyridine, acetonitrile, tetrahydrofuran or dich
- compounds of formula VIII-I can be generated by reacting compound of formula IV-I wherein Ll is a hydroxy group with a compound of formula V-I wherein L2 is a halogen atom or a hydroxyl group which needs to be activated prior to the reaction as for example a mesylate, tosylate or triflate as described above.
- the coupling is performed in presence of an inorganic base such as sodium hydride in a solvent such as dichloromethane or N,N-dimethylformamide at a temperature ranging between -20 0 C and 80 0 C.
- Removal of the protecting group PGl in compounds of formula VIII-I is carried out under standard conditions to generate compounds of formula II- 1.
- the benzyl carbamates are deprotected by hydrogenolysis over a noble catalyst (e.g. palladium on activated carbon).
- the Boc group is removed under acidic conditions such as hydrochloric acid in an organic solvent such as ethyl acetate, or trifuoroacetic acid neat or diluted in a solvent such as dichloromethane.
- the Alloc group is removed in presence of a palladium salt such as palladium acetate or tetrakis(triphenylphosphine)palladium(0) and an allyl cation scavenger such as morpholine, pyrrolidine, dimedone or tributylstannane between 0 0 C and 70 0 C in a solvent such as tetrahydrofuran.
- a palladium salt such as palladium acetate or tetrakis(triphenylphosphine)palladium(0)
- an allyl cation scavenger such as morpholine, pyrrolidine, dimedone or tributylstannane between 0 0 C and 70 0 C in a solvent such as tetrahydrofuran.
- the N-benzyl protected amines are deprotected by hydrogenolysis over a noble catalyst (e.g. palladium dihydroxide).
- Compounds of formula 1-1 wherein A3 is CH 2 can be obtained from intermediate II- 1 (Scheme 1) by reaction with a compound of formula III wherein LO is -CHO either in the presence of or followed by a reaction with a suitable reducing agent.
- the reaction between the amine and the aldehyde to form an intermediate imine is conducted in a solvent system allowing the removal of the formed water through physical or chemical means (e.g. distillation of the solvent- water azeotrope or presence of drying agents such as molecular sieves, magnesium sulfate or sodium sulfate).
- Such solvents are typically toluene, n- hexane, tetrahydrofuran, dichloromethane, N,N-dimethylformamide, N,N- dimethylacetamide, acetonitrile, 1,2-dichloroethane or mixture of solvents such as methanol: 1,2-dichloroethane.
- the reaction can be catalyzed by traces of acid (usually acetic acid).
- the imine is reduced subsequently or simultaneously with a suitable reagent such as sodium borohydride, sodium triacetoxyborohydride or sodium cyanoborohydride (R.O. and M.K. Hutchins, Comprehensive Organic Synthesis, B. M. Trost, I. Fleming, Eds; Pergamon Press: New York (1991), vol. 8, p. 25-78).
- the reaction is preferably carried out between 0 0 C and 60 0 C.
- Suitable coupling agents may be utilized such as, O-(J- azabenzotriazol- 1 -yl)- ⁇ WN',N'-tetramethyluronium hexafluorophosphate, 2-ethoxy- 1 - ethoxycarbonyl-l,2-dihydroquinoline, carbonyldiimidazole or diethylphosphorylcyanide.
- a base like triethylamine, 7V,N-diisopropylethylamine or pyridine can be added to perform the coupling.
- the peptidic coupling is conducted at a temperature comprised between -20 0 C and 80 0 C, in an inert solvent, preferably a dry aprotic solvent like dichloromethane, acetonitrile or 7V,iV-dimethylformamide and chloroform.
- an inert solvent preferably a dry aprotic solvent like dichloromethane, acetonitrile or 7V,iV-dimethylformamide and chloroform.
- the carboxylic acid can be activated by conversion into its corresponding acid chloride or its corresponding activated ester, such as the jV-hydroxysuccinimidyl ester (Org. Process Res.
- the generated activated entity can react at a temperature comprised between -20 0 C and 80 0 C with compound of formula II- 1 in an aprotic solvent like dichloromethane, chloroform, acetonitrile, 7V,iV-dimethylformamide and tetrahydrofuran to generate compound of formula 1-1.
- a base like triethylamine, 7V,iV-diisopropylethylamine, pyridine, sodium hydroxide, sodium carbonate, potassium carbonate can be added to perform the coupling.
- compounds of formula 1-1 wherein A3 is -CH 2 - can be obtained from intermediate II- 1 by reaction with a compound of formula III wherein LO is -CH 2 Y and Y is a leaving group like methylsulfonyl, tolylsulfonyl, trifluoromethylsulfonyl or halogen at a temperature between -20 0 C and 100 0 C in a dry aprotic solvent like dichloromethane, acetonitrile, N,N-dimethylformamide or tetrahydrofuran without or with a base such as potassium carbonate or N,N-diisopropylethylamine.
- Ll is a carboxylic acid C(O)-OH or its corresponding acid halide or other activated acyl derivatives, anhydride or mixed anhydride. All the other symbols have the same meanings as in formula I or in Scheme 1.
- reaction between compounds of formulae IV-2 wherein Ll is COOH and V-2 to generate compounds of formula 1-2 is performed with the addition of a coupling agent such as iV,iV-dicycloriexylcarbodiimide or the like, and optionally with the addition of 4- dimethylaminopyridine, imidazole or the like.
- a coupling agent such as iV,iV-dicycloriexylcarbodiimide or the like
- 4- dimethylaminopyridine imidazole or the like.
- the reaction between compounds of formula IV-2 wherein Ll is an acid halide, or any other activated acyl derivative and V-2 to generate compounds of formula 1-2 is performed in the presence of a base such as triethylamine or sodium hydride and optionally 4-dimethylaminopyridine.
- the acylation is conducted at a temperature comprised between -20 0 C and 60 0 C, in an inert solvent, preferably a dry aprotic solvent like dichloromethane, acetonitrile, N,N-dimethylformamide or chloroform.
- an inert solvent preferably a dry aprotic solvent like dichloromethane, acetonitrile, N,N-dimethylformamide or chloroform.
- compounds of formula 1-2 can be generated by first coupling compounds of formulae IV-2 and V-3 according to the methods described above to generate the intermediate VIII-2 and subsequent removal of the protecting group PGl and introduction of the substituent A3-G following procedures previously described for Scheme 1.
- Ll and L2 are SH, Br, Cl or the group OSO 2 R in which R is CH 3 , CF 3 , or tolyl and all the other symbols have the same meanings as in formula I or in Scheme 1.
- A2 in compound VIII-3 is a saturated or unsaturated 4 to 8-membered heterocyclodiyl group, which is linked to the -CH 2 -(CH 2 ) m -S- group via a ring nitrogen atom
- the compounds of formula VIII-3 can be obtained via reductive amination between VI-I and VII-I following procedures previously described in conjunction with Scheme 1 for the preparation of compounds of formula 1-1 wherein A3 is CH 2 by reaction of an intermediate II- 1 with a compound of formula III wherein LO is -CHO.
- compounds of formula VIII-3 can be obtained by reacting compounds of formula IV-3 for which Ll is SH with compounds of formula V-4 for which L2 is Br, Cl or the group OSO 2 R in which R is CH 3 , CF 3 , or tolyl in presence of a base such as sodium hydroxide, sodium hydride, sodium carbonate, potassium hydroxide, potassium carbonate, triethylamine in a solvent such as acetone, acetonitrile, ethanol, isopropanol or N,N- dimethylformamide at a temperature ranging between 0 0 C and 120 0 C.
- a base such as sodium hydroxide, sodium hydride, sodium carbonate, potassium hydroxide, potassium carbonate, triethylamine
- a solvent such as acetone, acetonitrile, ethanol, isopropanol or N,N- dimethylformamide
- compounds of formula VIII-3 can be obtained by reacting compounds of formula IV-3 for which Ll is is Br, Cl or the group OSO 2 R in which R is CH 3 , CF 3 , or tolyl with compounds of formula V-4 where L2 is SH.
- the reaction can be performed in presence of a palladium salt such as palladium acetate or tetrakis(triphenylphosphine)palladium(0) with the optional addition of a base such as sodium tert-butylatQ in a solvent such as toluene, N,N-dimethylformamide, dioxane at a temperature ranging from 0 0 C and 150 0 C.
- the intermediates VIII-3 are further transformed into compounds of formula 1-3 using synthetic routes previously described for Scheme 1.
- the protecting group PGl of compounds of formula V-4 can be removed and the product of this reaction can then be reacted with a compound of formula III according to the methods described above. Subsequently, these intermediates are reacted with compounds of formula IV-3 to give the compounds of formula 1-3 following the methods described above for the synthesis of compounds of formula VIII-I.
- an optically active form of a compound of the invention When an optically active form of a compound of the invention is required, it may be obtained by carrying out one of the above procedures using a pure enantiomer or diastereomer as a starting material, or by resolution of a mixture of the enantiomers or diastereomers of the final product or intermediate using a standard procedure.
- the resolution of enantiomers may be achieved by chromatography on a chiral stationary phase, such as REGIS PIRKLE COVALENT (R-R) WHELK-02, 10 ⁇ m, 100 A, 250 x 21.1 mm column.
- resolution of stereoisomers may be obtained by preparation and selective crystallization of a diastereomeric salt of a chiral intermediate or chiral product with a chiral acid, such as camphorsulfonic acid.
- a method of stereoselective synthesis may be employed, for example by using a chiral variant of a protecting group, a chiral catalyst or a chiral reagent where appropriate in the reaction sequence. Enzymatic techniques may also be useful for the preparation of optically active compounds and/or intermediates.
- compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt, a hydrate or solvate thereof and a pharmaceutically acceptable carrier;
- the compounds of number 1, 2, 3, 4, 5, 6, 7, 8, 9, 14, 15, 16, 17, 18, 19, 20, 28, 29, 30, 31, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55 and 56 indicated in Table 1 below are particularly advantageous for the treatment of infections by Staphylococcus aureus and/or Staphylococcus epidermidis and exhibit a MIC for said strains of generally ⁇ 2 mg/L.
- the compounds of number 2, 5, 9, 35, 36, 37, 38, 39, 40, 41, 42, 43, 45, 46, 47, 48, 49, 50, 52, 53 and 55 indicated in Table 1 below are particularly advantageous for the treatment of infections by Staphylococcus aureus and/or Staphylococcus epidermidis and/or Streptococcus pneumoniae and exhibit a MIC for said strains of generally ⁇ 2 mg/L.
- the compounds of number 9, 36, 37, 40, 44, 45, 46, 48, 49, 50, 51, 53 and 54 indicated in Table 1 below are particularly advantageous for the treatment of infections by Staphylococcus aureus and/or Staphylococcus epidermidis and/or Streptococcus pneumoniae and/or Escherichia coli and exhibit a MIC for said strains of generally ⁇ 4 mg/L, in most case of less than 2 mg/L.
- the compounds selected from the compounds of number 58, 62, 63, 67, 71, 73, 76, 78, 79, 80, 81, 94, 95, 101, 102,103, 104, 105, 113, 114, and 122 are particularly useful for the treatment of infections by Staphylococcus aureus and/or Staphylococcus epidermidis, the compounds of number 67, 78, 81, 95, 102, 103, 104, 105 and 122 for the treatment of infections by Staphylococcus aureus and/or Staphylococcus epidermidis and/or Streptococcus pneumoniae and the compounds of number 102 and 103 for use as a medicament against infections by Staphylococcus aureus and/or Staphylococcus epidermidis and/or Streptococcus pneumoniae and/or Escherichia coli.
- compounds of formula (I) are administered either individually, or optionally also in combination with another desired therapeutic agent, using the known and acceptable methods.
- Such therapeutically useful agents may be administered, for example, by one of the following routes: orally, for example in the form of dragees, coated tablets, pills, semi-solid substances, soft or hard capsules, solutions, emulsions or suspensions; parenterally, for example in the form of an injectable solution; rectally in the form of suppositories; by inhalation, for example in the form of a powder formulation or a spray; transdermally or intranasally.
- the therapeutically usable product may be mixed with pharmacologically inert, inorganic or organic pharmaceutical carrier substances, for example with lactose, sucrose, glucose, gelatine, malt, silica gel, starch or derivatives thereof, talcum, stearic acid or salts thereof, skimmed milk powder, and the like.
- pharmaceutical carrier substances such as, for example, vegetable oils, petroleum, animal or synthetic oils, wax, fat and polyols may be used.
- pharmaceutical carrier substances such as, for example, water, alcohols, aqueous saline solution, aqueous dextrose, polyols, glycerol, vegetable oils, petroleum and animal or synthetic oils may be used.
- pharmaceutical carrier substances such as, for example, vegetable oils, petroleum, animal or synthetic oils, wax, fat and polyols may be used.
- compressed gases that are suitable for this purpose, such as, for example, oxygen, nitrogen and carbon dioxide may be used.
- the pharmaceutically acceptable agents may also comprise additives for preserving and stabilising, emulsifiers, sweeteners, flavourings, salts for altering the osmotic pressure, buffers, encapsulation additives and antioxidants.
- Combinations with other therapeutic agents which are also encompassed by the present invention may comprise one, two or more other antimicrobial and anti- fungal active ingredients.
- the dose of the biologically active compound according to the invention may vary within wide limits and may be adjusted to individual requirements. Generally, a dose of 10 mg to 4000 mg per day is suitable, a preferred dose being from 50 to 3 000 mg per day. In suitable cases, the dose may also be below or above the stated values.
- the daily dose may be administered as a single dose or in a plurality of doses. A typical individual dose contains approximately 50 mg, 100 mg, 250 mg, 500 mg, 1 g or 2 g of the active ingredient.
- Mass spectra are generated using a q-Tof Ultima (Waters AG) mass spectrometer in the positive ESI mode.
- the system is equipped with the standard Lockspray interface; each intermediate is purified to the standard required for the subsequent stage and is characterized in sufficient detail to confirm that the assigned structure is correct; all analytical and preparative HPLC investigations on non-chiral phases are performed using RP-C 18 based columns; the following abbreviations may be used: Acetone-t/6: Deuterated acetone
- CDCI 3 Deuterated chloroform
- TLC Thin layer chromatography
- Example 109 the group A1 has the formula: -O-CH(CH 2 OCH 2 CF 3 )-CH 2 -.
- the numbers of the compounds of formula I used in the leftmost column of Table 1 is used in the whole application text for identifying the respective compounds, e.g. in Table 2 referring to the results in the tests for biological activity.
- 2-Bromo-ethanol (2.38 mL, 33.5 mmol, 1.0 eq) is added at room temperature to a stirred solution of piperidin-4-yl-carbamic acid tert-butyi ester (7.0 g, 33.5 mmol, 1.0 eq) in N,N- dimethylformamide (300 mL), followed by potassium carbonate (4.64 g, 33.5 mmol, 1.0 eq).
- solvent is evaporated and the residue is extracted with ethyl acetate (3 x 40 mL) and water (40 mL). p ⁇ of the aqueous layer is neutralized with a 0.1 N hydrochloric acid aqueous solution.
- Trifluoroacetic acid (580 ⁇ L, 7.52 mmol, 15.0 eq) is added at 0 0 C to a stirred solution of ⁇ 1- [2-(7-methoxy-quinoxalin-2-yloxy)-ethyl]-piperidin-4-yl ⁇ -carbamic acid tert-butyl ester (206 mg, 0.50 mmol, 1.0 eq) in dichloromethane (20 mL). After 15 hours stirring at room temperature, the reaction mixture is extracted with dichloromethane (3 x 20 mL) and water (20 mL) and the pH is adjusted to 12 by the addition of a IN sodium hydroxide aqueous solution.
- Trifluoroacetic acid (101 mL, 1.32 mol, 20.85 eq) is added to a stirred solution of (6- methoxy-[l,5]naphthyridine-3-yl)-carbamic acid tert-butyi ester (18.2 g, 66.11 mmol, 1.0 eq) in dichloromethane (500 mL). After 19 hours stirring at room temperature, the solution is evaporated to dryness, 6N sodium hydroxide aqueous solution is added to adjust pH to 9-10 and a lot of solid precipitated. The mixture is extracted with dichloromethane (200 mL) and the residue is extracted with ethyl acetate (3 x 250 mL).
- 6-methoxy-[l,5]naphthyridin-3-ylamino (13.6 g, 77.63 mmol, 1.0 eq) is added to a solution of sulfuric acid(20.7 mL, 388 mmol, 5.0 eq) in water (177 mL) at 0 ⁇ 4 0 C. Then a solution of sodium nitrite (5.89 g, 85.39 mmol, 1.1 eq) in water (136 mL) is added to this solution.
- Diethyl azodicarboxylate (3.96 g, 22.72 mmol, 3.0 eq) is added at room temperature to a stirred solution of [tr ⁇ r ⁇ -4-(2-hydroxy-ethyl)-cyclohexyl]-carbamic acid tert-butyi ester (1.84 g, 7.57 mmol, 1.0 eq), 6-methoxy-[l,5]naphthyridin-3-ol (1.80 g, 10.22 mmol, 1.35 eq) and triphenylphosphine (5.96 g, 22.72 mmol, 3.0 eq) in tetrahydrofuran (70 mL).
- the title compound is prepared as a white lyophilizated powder (19 mg, 15% yield) following Scheme 1 and in analogy to Example 2 using 3-oxo-3,4-dihydro-2H-pyrido[3,2- b][l,4]oxazine-6-carboxylic acid (49 mg, 0.25 mmol 1.0 eq) and trans -4-[2-(6-mQthoxy- [l,5]naphthyridin-3-yloxy)-ethyl]-cyclohexylamine (80 mg, 0.25 mmol, 1.0 eq) as starting materials.
- the title compound is prepared as a white amorphous lyophilizated solid following Scheme 1 and in analogy to Example 2 using 2-hydroxy-7-methoxy-quinoxaline, [trans-4-(2- hydroxy-ethyl)-cyclohexyl]-carbamic acid tert-butyi ester and 3-oxo-3,4-dihydro-2H- benzo[l,4]thiazine-6-carboxylic acid as starting materials.
- the title compound is prepared as a yellow solid (39 mg, 30% yield) following Scheme 1 and in analogy to Example 1 using 5-thiophen-2-yl-isoxazole-3-carboxylic acid (51 mg, 0.26 mmol 1.0 eq) and l-[2-(7-methoxy-quinoxalin-2-yloxy)-ethyl]-piperidin-4-ylamine (80 mg, 0.26 mmol, 1.0 eq) as starting materials.
- the title compound is prepared as a white amorphous lyophilizated solid (19 mg, 15% yield) following Scheme 1 and in analogy to Example 2 using 3-oxo-3,4-dihydro-2H- benzo[l ,4]oxazine-6-carboxylic acid (50 mg, 0.25 mmol 1.0 eq) and trans -4-[2-(6-mQthoxy- [l,5]naphthyridin-3-yloxy)-ethyl]-cyclohexylamine (80 mg, 0.25 mmol, 1.0 eq) as starting materials.
- Bromoacetic acid (5.34 g, 32.0 mmol, 0.5 eq) is added dropwise to 4-fluoro-2-nitro- phenylamine (10.0 g, 64.1 mmol, 1.0 eq) at 120 0 C.
- the reaction mixture is stirred for 2 hours at 120 0 C then xylene (10 mL) is added.
- the resulting reaction mixture is heated at 130 0 C for 1 hour, then it is made alkaline with 25% ammonia aqueous solution.
- Xylene is removed under reduced pressure and the residue is diluted with water (100 mL). The mixture is filtered at 60 0 C and the insoluble residue is extracted twice with 10% ammonia aqueous solution at 60 0 C.
- aqueous layer is acidified with hydrochloric acid to p ⁇ 5, the precipitated product is filtered, washed with water and ethanol, dried under vacuum to afford (4-fluoro-2-nitro-phenylamino)-acetic acid as a red solid (2.98 g, 34% yield).
- Iron powder (6.52 g, 116.8 mmol, 5.0 eq) is added at room temperature to a stirred solution of (4-fluoro-2-nitro-phenylamino)-acetic acid (6.85 g, 23.4 mmol, 1.0 eq) in glacial acetic acid (40 mL).
- the resulting suspension is heated at 90 0 C for 3 hours, then cooled to room temperature, diluted with ethyl acetate (40 mL), and filtered through silica gel.
- a mixture of 7-fluoro-quinoxalin-2-ol (2.60 g, 15.84 mmol, 1.0 eq) and phosphorus oxychloride (50 mL, 536.4 mmol, 34.0 eq) is refluxed for 1 hour, then concentrated, diluted with water (60 mL), basified to pH 7 by adding saturated sodium hydrogen carbonate aqueous solution, and extracted with ethyl acetate (3 x 100 mL).
- the title compound is prepared as a white amorphous lyophilizated solid following Scheme 1 and in analogy to Example 1 using 2-chloro-7-fluoro-quinoxaline, [trans-4-(2-hydroxy- ethyl)-cyclohexyl]-carbamic acid tert-butyl ester and 3-oxo-3,4-dihydro-2H- benzo[l,4]thiazine-6-carboxylic acid as starting materials.
- Example 8 3-oxo-3.,4-dihvdro-2H-benzo[l,41thiazine-6-carboxylic acid ⁇ l-[3-(7- methoxy-quinoxalin-2-yloxy)-propyll-azetidin-3-yl ⁇ -amide:
- the title compound is prepared as an off-white lyophilizated powder following Scheme 1 and in analogy to Example 1 using 2-chloro-7-methoxy-quinoxaline, 3-bromo-propan-l-ol, azetidin-3-yl-carbamic acid tert-butyl ester and 3-oxo-3,4-dihydro-2H-benzo[l,4]thiazine- 6-carboxylic acid as starting materials.
- Example 9 6-[f ⁇ l-[3-f7-methoxy-quinoxalin-2-yloxy)-propyll-piperidin-4-ylmethyl ⁇ - amino)-methyll- ⁇ H-pyrido[3. l 2-bl [l. l 41oxazin-3-one: Preparation of C- ⁇ 1 -r3-(7-methoxy-quinoxalin-2-yloxy)-propyl1-piperidin-4-vU - methylamine:
- the title compound is prepared as a brown viscous oil following Scheme 1 and in analogy to Example 1 using 2-chloro-7-methoxy-quinoxaline, 3-bromo-propan-l-ol and piperidin-4- ylmethyl-carbamic acid tert-butyl ester as starting materials.
- 2,3-dihydro-benzo[l,4]dioxine-6-carbaldehyde (153 mg, 0.93 mmol, 1.0 eq) is added at room temperature to a stirred solution of 4-methylamino-piperidine-l -carboxylic acid tert-butyl ester (200 mg, 0.93 mmol, 1.0 eq) in 1 ,2-dichloroethane (8 mL) and methanol (2 mL), followed by acetic acid (61 ⁇ L, 1.07 mmol, 1.15 eq) and sodium cyanoborohydride (76 mg, 1.21 mmol, 1.3 eq).
- Trifluoroacetic acid (591 ⁇ L, 7.67 mmol, 15.0 eq) is added at 0 0 C to a stirred solution of 4- [(2, 3-dihydro-benzo[l,4]dioxin-6-ylmethyl)-methyl-amino]-piperidine-l -carboxylic acid tert-butyl ester (195 mg, 0.51 mmol, 1.0 eq) in dichloromethane (10 mL). After 3 hours stirring at room temperature, the reaction mixture is extracted with dichloromethane (3 x 10 mL) and water (10 mL) and the pH is adjusted to 12 by the addition of a IN sodium hydroxide aqueous solution.
- 2-Bromo-ethanol (36 ⁇ L, 0.51 mmol, 1.0 eq) is added at room temperature to a stirred solution of (2,3-dihydro-benzo[l,4]dioxin-6-ylmethyl)-methyl-piperidin-4-yl-amine (148 mg, 0.51 mmol, 1.0 eq) in N,N-dimethylformamide (4 mL), followed by potassium carbonate (70 mg, 0.51 mmol, 1.0 eq). After 15 hours stirring at room temperature, solvent is evaporated and the residue is extracted with ethyl acetate (3 x 8 mL) and water (8 mL).
- the title compound is prepared as a yellow amorphous lyophilizated solid following Scheme 1 and in analogy to Examples 1 and 9 using 2-chloro-7-methoxy-quinoxaline, 3-bromo- propan-1-ol, piperidin-3-yl-carbamic acid tert-butyi ester and 3-oxo-3,4-dihydro-2H- benzo[l,4]thiazine-6-carbaldehyde as starting materials.
- Example 12 3-oxo-3.,4-dihvdro-2H-benzo[l,41thiazine-6-carboxylic acid ⁇ l-[2-(8- methoxy-quinoxalin-2-yloxy)-ethyll-piperidin-4-yl ⁇ -amide:
- the title compound is prepared as an off-white lyophilizated powder following Scheme 1 and in analogy to Example 1 using ⁇ l-[2-(8-methoxy-quinoxalin-2-yloxy)-ethyl]-piperidin- 4-yl ⁇ -carbamic acid tert-butyl ester and 3-oxo-3,4-dihydro-2H-benzo[l,4]thiazine-6- carboxylic acid as starting materials.
- the title compound is prepared as a yellow lyophilizated powder following Scheme 1 and in analogy to Examples 1 and 12 using 2-chloro-7-nitro-quinoxaline, [l-(2-hydroxy-ethyl)- piperidin-4-yl]-carbamic acid tert-butyi ester and 3-oxo-3,4-dihydro-2H-benzo[l,4]thiazine- 6-carboxylic acid as starting materials.
- Example 14 3-oxo-3.,4-dihvdro-2H-benzo[l,41thiazine-6-carboxylic acid ⁇ l-[3.,3i3- trifluoro-2-f7-methoxy-quinoxalin-2-yloxy)-propyll-piperidin-4-yl ⁇ -amide:
- the title compound is prepared as an off-white lyophilizated powder following Scheme 1 and in analogy to Example 1 using 2-chloro-7-methoxy-quinoxaline, 3-bromo-l,l,l- trifluoro-2-propanol, piperidin-4-yl-carbamic acid tert-butyl ester and 3-oxo-3,4-dihydro- 2H-benzo[l,4]thiazine-6-carboxylic acid as starting materials.
- Example 15 T-chloro-S-oxo-S ⁇ -dihydro ⁇ H-benzon ⁇ lthiazine- ⁇ -carboxylic acid ⁇ 1- r2-(7-methoxy-quinoxalin-2-yloxy)-ethyll-piperidin-4-yl ⁇ -amide:
- the title compound is prepared as white lyophilizated powder (11 mg, 16% yield) following Scheme 1 and in analogy to Example 1 using 7-chloro-3-oxo-3,4-dihydro-2H- benzo[l,4]thiazine-6-carboxylic acid (31 mg, 0.13 mmol, 1.0 eq) and l-[2-(7-methoxy- quinoxalin-2-yloxy)-ethyl]-piperidin-4-ylamine (40 mg, 0.13 mmol, 1.0 eq) as starting materials.
- Example 16 T-chloro-B-oxo-B ⁇ -dihydro ⁇ H-benzon ⁇ lthiazine- ⁇ -carboxylic acid ⁇ 1- [2-f6-methoxy-[l,51naphthyridin-3-yloxy)-ethyll-piperidin-4-yl ⁇ -amide:
- [l-(2-hydroxy-ethyl)-piperidin-4-yl]-carbamic acid tert-butyl ester (50 mg, 0.19 mmol, 1.0 eq) is added at room temperature to a stirred solution of 6-methoxy-[ 1 ,5]naphthyridin-3-ol (37 mg, 0.19 mmol, 1.0 eq) in tetrahydrofuran (5 mL), followed by triphenylphosphine polymer-bound (3 mmol/g, 193 mg, 0.58 mmol, 3.0 eq) and diisopropyl azodicarboxylate (115 ⁇ L, 0.58 mmol, 3.0 eq).
- Triethylamine (515 ⁇ L, 3.69 mmol, 0.95 eq) is added at 0 0 C to a stirred solution of [l-(2- hydroxy-ethyl)-piperidin-4-yl]-carbamic acid tert-butyi ester (1.0 g, 3.89 mmol, 1.0 eq) in dichloromethane (40 mL), followed by the dropwise addition of methanesulfonyl chloride (286 ⁇ L, 3.69 mmol, 0.95 eq). After 2 hours stirring at 0 0 C, the reaction mixture is extracted with dichloromethane (3 x 30 mL) and water (30 mL).
- reaction mixture is irradiated by microwaves at 110 0 C for 10 minutes, then solvent is evaporated, and the residue is extracted with ethyl acetate (3 x 10 mL) and water (10 mL).
- the combined organic layers are dried over sodium sulfate, filtered and concentrated to give a residue that is purified by column chromatography (silica gel, eluent: cyclohexane: ethyl acetate .'methanol, 1:1:0 to 0:9:1, v/v/v) to afford ⁇ l-[2-(6-methoxy-[l,5]naphthyridin-3- yloxy)-ethyl]-piperidin-4-yl ⁇ -carbamic acid tert-butyi ester as an orange solid (27 mg, 29% yield).
- the title compound is prepared as an off-white lyophilizated powder following Scheme 1 and in analogy to Examples 1 and 12 using 2-chloro-7-methoxy-quinoline, [l-(2-hydroxy- ethyl)-piperidin-4-yl]-carbamic acid tert-butyi ester and 3-oxo-3,4-dihydro-2H-pyrido[3,2- b] [l,4]thiazine-6-carboxylic acid as starting materials.
- Example 18 3-oxo-3.,4-dihvdro-2H-benzo[l,41thiazine-6-carboxylic acid ⁇ l-[2-(7- methoxy-[l,51naphthyridin-2-yloxy)-ethyll-piperidin-4-yl ⁇ -amide:
- Potassium carbonate (13.84 g, 100.1 mmol, 2.0 eq) is added at room temperature to a stirred solution of 6-methoxy-[l,5]naphthyridin-3-ol (9.8 g, 50.06 mmol, 1.0 eq) in acetone (300 mL), followed by iodomethane (3.74 mL, 60.1 mmol, 1.2 eq). After 4 hours stirring under reflux conditions, the solid is removed by filtration and the filtrate is concentrated to give a residue that is extracted with ethyl acetate (3 x 100 mL) and water (100 mL).
- the title compound is prepared as an off-white lyophilizated powder following Scheme 1 and in analogy to Example 1 using 2-chloro-7-methoxy-[l,5]naphthyridine, [1 -(2 -hydroxy- ethyl)-piperidin-4-yl]-carbamic acid tert-butyl ester and 3-oxo-3,4-dihydro-2H- benzo[l,4]thiazine-6-carboxylic acid as starting materials.
- Example 19 T-chloro-B-oxo-B ⁇ -dihydro ⁇ H-benzon ⁇ lthiazine- ⁇ -carboxylic acid ⁇ 1- [2-f7-methoxy-[l,51naphthyridin-2-yloxy)-ethyll-piperidin-4-yl ⁇ -amide:
- the title compound is prepared as an off-white lyophilizated powder following Scheme 1 and in analogy to Example 1 using 2-chloro-7-methoxy-[l,5]naphthyridine, [l-(2-hydroxy- ethyl)-piperidin-4-yl]-carbamic acid tert-butyi ester and 7-chloro-3-oxo-3,4-dihydro-2H- benzo[l,4]thiazine-6-carboxylic acid as starting materials.
- Example 20 3-oxo-3.,4-dihvdro-2H-pyrido[3. l 2-bl[l. l 41thiazine-6-carboxylic acid ⁇ l-[2- (7-methoxy-quinoxalin-2-yloxy)-ethyll-piperidin-4-yl ⁇ -amide:
- the title compound is prepared as an off-white lyophilizated powder following Scheme 1 and in analogy to Example 1 using 2-chloro-7-methoxy-quinoxaline, [l-(2-hydroxy-ethyl)- piperidin-4-yl]-carbamic acid tert-butyi ester and 3-oxo-3,4-dihydro-2H-pyrido[3,2- b][l,4]thiazine-6-carboxylic acid as starting materials.
- the title compound is prepared as a white amorphous lyophilizated solid following Scheme 1 and in analogy to Example 1 using 2-chloro-quinoxaline, [l-(2-hydroxy-ethyl)-piperidin- 4-yl]-carbamic acid tert-butyl ester and 3-oxo-3,4-dihydro-2H-benzo[l,4]thiazine-6- carboxylic acid as starting materials.
- the title compound is prepared as an off-white lyophilizated powder following Scheme 1 and in analogy to Example 1 using 2-chloro-7-methoxy-quinoxaline, 2-bromo-ethanol, azetidin-3-yl-carbamic acid tert-butyi ester and 3-oxo-3,4-dihydro-2H-benzo[l,4]thiazine- 6-carboxylic acid as starting materials.
- the title compound is prepared as a white solid following Scheme 1 and in analogy to Example 1 using 2-chloro-7-methoxy-quinoxaline, 3-bromo-propan-l-ol, pyrrolidin-3-yl- carbamic acid tert-butyl ester and 3-oxo-3,4-dihydro-2H-benzo[l,4]thiazine-6-carboxylic acid as starting materials.
- Example 24 T-chloro-S-oxo-S ⁇ -dihydro ⁇ H-benzon ⁇ lthiazine- ⁇ -carboxylic acid ⁇ 1- [2-f7-methoxy-quinoxalin-2-yloxy)-ethyll-piperidin-4-ylmethyl ⁇ -amide:
- the title compound is prepared as a yellow viscous oil following Scheme 1 and in analogy to Example 9 using 2-chloro-7-methoxy-quinoxaline, [l-(2-hydroxy-ethyl)-piperidin-4-yl]- carbamic acid tert-butyl ester and 3-oxo-3,4-dihydro-2H-benzo[l,4]thiazine-6-carbaldehyde as starting materials.
- Paraformaldehyde (29 mg, 0.10 mmol, 1.0 eq) is added at room temperature to a stirred solution of 6-( ⁇ l-[2-(7-methoxy-quinoxalin-2-yloxy)-ethyl]-piperidin-4-ylamino ⁇ - methyl)-4H-benzo[l,4]thiazin-3-one (50 mg, 0.10 mmol, 1.0 eq) in 1 ,2-dichloroethane (2 mL) and methanol (0.5 mL), followed by acetic acid (7 ⁇ L, 0.12 mmol, 1.3 eq) and sodium cyanoborohydride (9 mg, 0.12 mmol, 1.3 eq).
- Example 26 S-thiophen ⁇ -yl-isoxazole-B-carboxylic acid ⁇ l-[2-f7-methoxy-quinoxalin- 2-yloxy)-ethyll-pyrrolidin-3-ylmethyl ⁇ -amide: The title compound is prepared as an orange semi-solid following Scheme 1 and in analogy to Example 1 using 2-chloro-7-methoxy-quinoxaline, 2-bromo-ethanol, pyrrolidin-3- ylmethyl-carbamic acid tert-butyi ester and S-thiophen-l-yl-isoxazole-S-carboxylic acid as starting materials.
- Example 27 T-chloro-B ⁇ -dihydro ⁇ H-benzon ⁇ lthiazine- ⁇ -carboxylic acid ⁇ l-[3-(7- methoxy-quinoxalin-2-yloxy)-propyll-pyrrolidin-3-ylmethyl ⁇ -amide:
- the title compound is prepared as a light yellow lyophilizated powder following Scheme 1 and in analogy to Example 1 using 2-chloro-7-methoxy-quinoxaline, 3-bromo-propan-l-ol, pyrrolidin-3-ylmethyl-carbamic acid tert-butyi ester and 7-chloro-3,4-dihydro-2H- benzo[l,4]thiazine-6-carboxylic acid as starting materials.
- Example 28 ⁇ -methoxy-quinoline-B-carboxylic acid fra «s-4-[f3-oxo-3.,4-dihvdro-2H- benzo [ 1 ,41 thiazine-6-carboiryl)-aminol -cyclohexylmethyl ester:
- Potassium carbonate (877 mg, 6.34 mmol, 1.05 eq) is added at room temperature to a stirred solution of trans -4-tert-butoxycarbonylamino-cyclohexanecarboxylic acid (1.5O g, 6.04 mmol, 1.0 eq) in 7V,iV-dimethylformamide (30 mL), followed by methyl iodide (395 ⁇ L, 6.34 mmol, 1.05 eq). After 5 hours stirring at room temperature, solvent is evaporated and the residue is extracted with ethyl acetate (3 x 30 mL) and water (30 mL).
- reaction mixture is extracted with dichloromethane (3 x 50 mL) and water (50 mL) and the pH is adjusted to 12 by the addition of a IN sodium hydroxide aqueous solution.
- the combined organic layers are dried over sodium sulfate, filtered and concentrated to afford tr ⁇ r ⁇ -4-amino-cyclohexanecarboxylic acid methyl ester as a yellow oil (1.53 g, 79% yield).
- Example 29 ⁇ -methoxy-rLSlnaphthyridine-B-carboxylic acid trans-4- ⁇ (2,3-d ⁇ hydro- benzo [ 1 ,41 dioxin-6-ylmethyl)-aminol -cyclohexylmethyl ester: Preparation of frvms-4-r(2,3-dihvdro-benzor 1 ,41dioxin-6-ylmethyl)-aminol- cyclohexanecarboxylic acid methyl ester:
- 2,3-Dihydro-benzo[l,4]dioxine-6-carbaldehyde (198 mg, 1.21 mmol, 1.0 eq) is added at room temperature to a stirred solution of tr ⁇ r ⁇ -4-amino-cyclohexanecarboxylic acid methyl ester (200 mg, 1.21 mmol, 1.0 eq) in 1 ,2-dichloroethane (8 mL) and methanol (2 mL), followed by acetic acid (80 ⁇ L, 1.39 mmol, 1.15 eq) and sodium cyanoborohydride (99 mg, 1.57 mmol, 1.3 eq).
- reaction mixture is extracted with dichloromethane (3 x 20 mL) and a saturated sodium hydrogen carbonate aqueous solution (20 mL). The combined organic layers are dried over sodium sulfate, filtered and concentrated to afford tr ⁇ «5 r -4-[(2,3-dihydro-benzo[l,4]dioxin-6-ylmethyl)- amino]-cyclohexanecarboxylic acid methyl ester as an orange oil (359 mg, 92% yield).
- Lithium aluminium hydride (1.0 M solution in tetrahydrofuran, 2.20 mL, 2.20 mmol, 2.0 eq) is added at 0 0 C to a stirred solution of tr ⁇ r ⁇ -4-[(2,3-dihydro-benzo[l,4]dioxin-6- ylmethyl)-amino]-cyclohexanecarboxylic acid methyl ester (355 mg, 1.10 mmol, 1.0 eq) in tetrahydrofuran (30 mL). After 2 hours stirring at 0 0 C, the reaction mixture is cautiously quenched with ice-water (6 mL).
- Tetrahydrofuran is evaporated and the crude is extracted with ethyl acetate (3 x 50 mL) and water (50 mL). The combined organic layers are dried over sodium sulfate, filtered and concentrated to afford ⁇ trans-4-[(2,3-dihydro- benzo[l,4]dioxin-6-ylmethyl)-amino]-cyclohexyl ⁇ -methanol as an orange oil (322 mg, 99% yield).
- 6-Methoxy-[l,5]naphthyridine-3-carboxylic acid (100 mg, 0.44 mmol, 1.0 eq) is added at room temperature to a stirred solution of tr ⁇ r ⁇ - ⁇ 4-[(2,3-dihydro-benzo[l,4]dioxin-6- ylmethyl)-amino]-cyclohexyl ⁇ -methanol (129 mg, 0.44 mmol, 1.0 eq) in N,N- dimethylformamide (4 mL), followed by N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (93 mg, 0.48
- Example 30 ⁇ -methoxy-rLSlnaphthyridine-S-carboxylic acid trans-4- [(3-0X0-3,4- dihydro-2H-pyrido[3. l 2-bl[l. l 41oxazine-6-carbonyl)-aminol-cvclohexylmethyl ester:
- the title compound is prepared as a light brown semisolid following Scheme 2 and in analogy to Example 28 using 3-oxo-3,4-dihydro-2H-pyrido[3,2-b][l,4]oxazine-6-carboxylic acid, tr ⁇ r ⁇ -4-amino-cyclohexanecarboxylic acid methyl ester and 6-methoxy- [l,5]naphthyridine-3-carboxylic acid as starting materials.
- Example 31 6-methoxy-[l,51naphthyridine-3-carboxylic acid / ⁇ ms-4-[2-(thiophen-2- ylsulfanyD-ethylaminol -cyclohexylmethyl ester: Preparation of 2-(2-bromo-ethylsulfanyl)-thiophene:
- Potassium carbonate (2.50 g, 18.07 mmol, 2.1 eq) is added at room temperature to a stirred solution of thiophene-2 -thiol (813 ⁇ L, 8.61 mmol, 1.0 eq) in 1 ,2-dibromoethane (10 mL) and the resulting mixture is stirred at 78 0 C for 3 hours. Then potassium carbonate is removed by filtration and the mother liquid is concentrated to give a crude that is purified by column chromatography (silica gel, eluent: cyclohexane 100%) to afford 2-(2-bromo- ethylsulfanyl)-thiophene as a light yellow oil (1.86 g, 95% yield).
- Example 32 ⁇ -methoxy-quinoline-B-carboxylic acid trans-4- ⁇ (2,3-d ⁇ hydro- benzo[l,41dioxin-6-ylmethyl)-methyl-aminol-cvclohexylmethyl ester:
- Example 28 using 6-methoxy-quinoline-3-carboxylic acid and frvms-4-[(2,3-dihydro- benzo[l,4]dioxin-6-ylmethyl)-methyl-amino]-cyclohexanecarboxylic acid methyl ester as starting materials.
- Example 33 ⁇ -methoxy-quinoline-B-carboxylic acid trans-4- ⁇ (2,3-dihydro- benzo [ 1 ,41 dioxin-6-ylmethyl)-aminol -cyclohexylmethyl ester:
- the title compound is prepared as an off-white semisolid (24 mg, 26% yield) following Scheme 2 and in analogy to Example 28 using ⁇ -methoxy-quinoline-S-carboxylic acid (40 mg, 0.19 mmol, 1.0 eq) and ⁇ tr ⁇ «5-4-[(2,3-dihydro-benzo[l,4]dioxin-6-ylmethyl)-amino]- cyclohexyl ⁇ -methanol (55 mg, 0.19 mmol, 1.0 eq) as starting materials.
- tr ⁇ r ⁇ -(4-Hydroxymethyl-cyclohexyl)-carbamic acid tert-butyl ester (480 mg, 2.46 mmol, 1.0 eq) is added at room temperature to a stirred solution of 6-methoxy-quinoline-3-carboxylic acid (564 mg, 2.46 mmol, 1.0 eq) in dichloromethane (15 mL), followed by 1- hydroxybenzotriazole (532 mg, 3.94 mmol, 1.6 eq), 7V-(3-dimethylaminopropyl)-N'- ethylcarbodiimide hydrochloride (1.04 g, 5.41 mmol, 2.2 eq) and triethylamine (754 ⁇ L, 5.41 mmol, 2.2 eq).
- Trifluoroacetic acid (1.45 mL, 18.82 mmol, 10.0 eq) is added at 0 0 C to a stirred solution of 6-methoxy-quinoline-3-carboxylic acid tr ⁇ r ⁇ -4-tert-butoxycarbonylamino- cyclohexylmethyl ester (780 mg, 1.88 mmol, 1.0 eq) in dichloromethane (10 mL).
- 2,3-Dihydro-benzo[l,4]dioxine-6-carbaldehyde (188 mg, 1.14 mmol, 1.8 eq) is added at room temperature to a stirred solution of the trifluoroacetic acid salt of 6-methoxy- quinoline-3-carboxylic acid tr ⁇ r ⁇ -4-amino-cyclohexylmethyl ester (200 mg, 0.64 mmol, 1.0 eq) in 1 ,2-dichloroethane (10 mL), followed by sodium triacetoxyborohydride (1.35 g, 6.36 mmol, 10.0 eq).
- Example 34 ⁇ -methoxy-quinoline-B-carboxylic acid trans-4- ⁇ (2,3-d ⁇ hydro- benzo[l,41dioxin-6-ylmethyl)-ethyl-aminol-cvclohexylmethyl ester:
- Ethyl iodide (51 ⁇ L, 0.63 mmol, 8.0 eq) is added at room temperature to a stirred solution of 6-methoxy-quinoline-3-carboxylic acid frvms-4-[(2,3-dihydro-benzo[l ,4]dioxin-6- ylmethyl)-amino]-cyclohexylmethyl ester (37 mg, 0.08 mmol, 1.0 eq) in N,N- dimethylformamide (0.5 mL), followed by silver oxide (73 mg, 0.31 mmol, 4.0 eq).
- Example 35 S-thiophen-l-yl-isoxazole-B-carboxylic acid ⁇ l-[2-(7-methoxy- quinoxalin-2-ylsulfanyl)-ethyll-piperidin-4-yl ⁇ -amide: Preparation of 2-(7-methoxy-quinoxalin-2-ylsulfanyl)-ethanol:
- 2-Mercaptoethanol (2.5 g, 32.06 mmol, 1.2 eq) is added at room temperature to a stirred solution of 2-chloro-7-methoxy-quinoxaline (5.2 g, 26.72 mmol, 1.0 eq) in N,N- dimethylformamide (160 mL), followed by potassium carbonate (7.4 g, 53.44 mol, 2.0 eq). After 15 hours stirring at room temperature, solvent is evaporated and the residue is extracted with ethyl acetate (3 x 150 mL) and water (100 mL).
- Dess-Martin periodinane (10.8 g, 25.4 mmol, 2.0 eq) is added at 0 0 C to a stirred solution of 2-(7-methoxy-quinoxalin-2-ylsulfanyl)-ethanol (3.0 g, 12.7 mmol, 1.0 eq) in dichloromethane (100 mL).
- the reaction mixture is stirred 0 0 C for 30 minutes then at room temperature for 3 hours.
- a saturated sodium thiosulfate aqueous solution 50 mL
- a saturated sodium hydrogen carbonate aqueous solution 50 mL
- the resulting mixture is stirred for 30 minutes, then extracted with dichloromethane (3 x 100 mL).
- Piperidin-4-yl-carbamic acid tert-butyl ester (2.82 g, 14.09 mmol, 1.5 eq) is added at room temperature to a stirred solution of (7-methoxy-quinoxalin-2-ylsulfanyl)-acetaldehyde (2.2 g, 9.39 mmol, 1.0 eq) in 1 ,2-dichloroethane (80 mL), followed by sodium triacetoxyborohydride (3.98 g, 18.78 mmol, 2.0 eq). After 15 hours stirring at room temperature, the reaction mixture is extracted with dichloromethane (3 x 60 mL) and a saturated sodium hydrogen carbonate aqueous solution (60 mL).
- Trifluoroacetic acid (5.41 mL, 70.2 mmol, 15.0 eq) is added at 0 0 C to a stirred solution of ⁇ 1 -[2-(7-methoxy-quinoxalin-2-ylsulfanyl)-ethyl]-piperidin-4-yl ⁇ -carbamic acid tert-butyl ester (2.0 g, 4.68 mmol, 1.0 eq) in dichloromethane (200 mL). After 15 hours stirring at room temperature, the reaction mixture is extracted with dichloromethane (3 x 50 mL) and water (50 rnL) and the pH value adjusted to 12 by the addition of a IN sodium hydroxide aqueous solution.
- 5-Thiophen-2-yl-isoxazole-3-carboxylic acid 43 mg, 0.22 mmol, 1.0 eq
- l-[2-(7-methoxy-quinoxalin-2-ylsulfanyl)-ethyl]- piperidin-4-ylamine 70 mg, 0.22 mmol, 1.0 eq
- 7V,iV-dimethylformamide 5 mL
- 1-hydroxybenzotriazole 32 mg, 0.24 mmol, 1.1 eq
- N-(3- dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride 47 mg, 0.25 mmol, 1.15 eq
- 7V,iV-diisopropylethylamine 83 ⁇ L, 0.48 mmol, 2.25 eq).
- Example 37 T-chloro-S-oxo-S ⁇ -dihydro ⁇ H-benzon ⁇ lthiazine- ⁇ -carboxylic acid ⁇ 1- r2-(7-methoxy-quinoxalin-2-ylsulfanyl)-ethyll-piperidin-4-yl ⁇ -amide:
- Example 38 ⁇ l-[2-f7-methoxy-quinoxalin-2-ylsulfanyl)-ethyll-piperidin-4-yl ⁇ -[2- (thiophen-2-ylsulfairyl)-ethyll-amine: 2-(2-Bromo-ethylsulfanyl)-thiophene (51 mg, 0.22 mmol, 1.0 eq) is added at room temperature to a stirred solution of l-[2-(7-methoxy-quinoxalin-2-ysulfanyl)-ethyl]- piperidin-4-ylamine (70 mg, 0.22 mmol, 1.0 eq) in acetonitrile (5 mL).
- the title compound is prepared as a yellow solid (61 mg, 56% yield) following Scheme 3 and in analogy to Example 35 using 2,3-dihydro-benzo[l,4]dioxine-6-carboxylic acid (39 mg, 0.22 mmol 1.0 eq) and l-[2-(7-methoxy-quinoxalin-2-ylsulfanyl)-ethyl]-piperidin-4- ylamine (70 mg, 0.22 mmol, 1.0 eq) as starting materials.
- Example 40 6-f ⁇ l-[2-f7-methoxy-quinoxalin-2-ylsulfanyl)-ethyll-piperidin-4-yl ⁇ - amino)-methyl)- ⁇ H-benzo[l,41oxazin-3-one: 3-Oxo-3,4-dihydro-2H-benzo[l,4]oxazine-6-carbaldehyde (354 mg, 2.00 mmol, 1.0 eq) is added at room temperature to a stirred solution of l-[2-(7-methoxy-quinoxalin-2- ylsulfanyl)-ethyl]-piperidin-4-ylamine (0.65 g, 2.00 mmol, 1.0 eq) in 1 ,2-dichloroethane (4 mL) and methanol (1 mL), followed by acetic acid (0.11 mL, 2.00 mmol, 1.0 eq) and sodium cyanoborohydride (160 mg,
- Example 42 ⁇ l-[2-f7-methoxy-quinoxalin-2-ylsulfanyl)-ethyll-piperidin-4-yl ⁇ -f5- thiophen-2-yl-isoxazol-3-ylmethyl)-amine
- the title compound is prepared as a yellow oil (57 mg, 52% yield) following Scheme 3 and in analogy to Example 40 using 5-thiophen-2-yl-isoxazole-3-carbaldehyde (43 mg, 0.22 mmol 1.0 eq) and l-[2-(7-methoxy-quinoxalin-2-ylsulfanyl)-ethyl]-piperidin-4-ylamine (70 mg, 0.22 mmol, 1.0 eq) as starting materials.
- the title compound is prepared as a yellow foam (30 mg, 29% yield) following Scheme 3 and in analogy to Example 40 using paraformaldehyde (37 mg, 0.64 mmol 3.0 eq) and (2,3- dihydro-benzo[l,4]dioxin-6-ylmethyl)- ⁇ l-[2-(7-methoxy-quinoxalin-2-ylsulfanyl)-ethyl]- piperidin-4-yl ⁇ -amine (100 mg, 0.22 mmol, 1.0 eq) as starting materials.
- Example 44 7-chloro-3.,4-dihvdro-2H-benzo[l,41thiazine-6-carboxylic acid ⁇ l-[2-(7- methoxy-quinoxalin-2-ylsulfanyl)-ethyll-piperidin-4-yl ⁇ -amide: The title compound is prepared as an off-white solid (37 mg, 51% yield) following Scheme 3 and in analogy to Example 35 using 7-chloro-3,4-dihydro-2H-benzo[l,4]thiazine-6- carboxylic acid (29 mg, 0.12 mmol 1.0 eq) and l-[2-(7-methoxy-quinoxalin-2-ylsulfanyl)- ethyl]-piperidin-4-ylamine as starting materials.
- Example 45 6-f ⁇ l-[2-f7-methoxy-quinoxalin-2-ylsulfanyl)-ethyll-piperidin-4- ylamino ⁇ -methyl)- ⁇ H-pyrido[3. l 2-bl [l. l 41oxazin-3-one:
- the title compound is prepared as a yellow waxy solid (54 mg, 48% yield) following Scheme 3 and in analogy to Example 40 using 3-oxo-3,4-dihydro-2H-benzo[l,4]thiazine-6- carbaldehyde (42 mg, 0.22 mmol 1.0 eq) and l-[2-(7-methoxy-quinoxalin-2-ylsulfanyl)- ethyl]-piperidin-4-ylamine (70 mg, 0.22 mmol, 1.0 eq) as starting materials.
- the title compound is prepared as a yellow solid (67 mg, 20% yield) following Scheme 3 and in analogy to Example 40 using acetaldehyde (181 ⁇ g, 3.21 mmol 5.0 eq) and (2,3- dihydro-benzo[l,4]dioxin-6-ylmethyl)- ⁇ l-[2-(7-methoxy-quinoxalin-2-ylsulfanyl)-ethyl]- piperidin-4-yl ⁇ -amine (300 mg, 0.64 mmol, 1.0 eq) as starting materials.
- Example 48 7-chloro-6-f ⁇ l-[2-f7-methoxy-quinoxalin-2-ylsulfanyl)-ethyll-piperidin- 4-ylamino ⁇ -methyl)- ⁇ H-benzo[l,41thiazin-3-one:
- the title compound is prepared as a yellow solid (24 mg, 35% yield) following Scheme 3 and in analogy to Example 40 using 7-chloro-3-oxo-3,4-dihydro-2H-benzo[l,4]thiazine-6- carbaldehyde (30 mg, 0.12 mmol 1.0 eq) and l-[2-(7-methoxy-quinoxalin-2-ylsulfanyl)- ethyl]-piperidin-4-ylamine (40 mg, 0.12 mmol, 1.0 eq) as starting materials.
- Example 49 (7-chloro-3,4-dihvdro-2H-benzori,41thiazin-6-ylmethylHl-r2-(7- methoxy-quinoxalin-2-ylsulfanyl)-ethyll-piperidin-4-yl ⁇ -amine:
- Example 50 3-oxo-3.,4-dihvdro-2H-pyrido[3. l 2-bl[l. l 41thiazine-6-carboxylic acid ⁇ l-[2- (7-methoxy-quinoxalin-2-ylsulfanyl)-ethyll-piperidin-4-yl ⁇ -amide:
- Example 51 7-chloro-3-oxo-3.,4-dihvdro-2H-pyrido[3.
- 2-bl [l ⁇ lthiazine- ⁇ -carboxylic acid ⁇ l-[2-f7-methoxy-quinoxalin-2-ylsulfanyl)-ethyll-piperidin-4-yl ⁇ -amide:
- Dess-Martin periodinane 400 mg, 0.94 mmol, 2.0 eq is added at 0 0 C to a stirred solution of 2-(6-methoxy-quinolin-3-ylsulfanyl)-ethanol (130 mg, 0.55 mmol, 1.0 eq) in dichloromethane (5 mL). The reaction mixture is stirred at room temperature for 1 hour, concentrated to give a crude product that is directly engaged in the next step (130 mg, 100%).
- Trifluoroacetic acid (1.88 mL, 24.2 mmol, 15.0 eq) is added at 0 0 C to a stirred solution of ⁇ 1 -[2-(6-methoxy-quinolin-3-ylsulfanyl)-ethyl]-piperidin-4-yl ⁇ -carbamic acid tert-butyl ester (724 mg, 1.61 mmol, 1.0 eq) in dichloromethane (75 mL). After 15 hours stirring at room temperature, the reaction mixture is extracted with dichloromethane (3 x 50 mL) and water (50 mL) and the pH value adjusted to 12 by the addition of a IN sodium hydroxide aqueous solution.
- Example 54 T-chloro-B-oxo-B ⁇ -dihydro ⁇ H-benzon ⁇ lthiazine- ⁇ -carboxylic acid ⁇ 1- [2-f6-methoxy-quinolin-3-ylsulfanyl)-ethyll-piperidin-4-yl ⁇ -amide:
- Example 56 7-chloro-3-oxo-3.,4-dihvdro-2H-pyrido[3. l 2-bl [l ⁇ lthiazine- ⁇ -carboxylic acid ⁇ l-[2-f6-methoxy-quinolin-3-ylsulfanyl)-ethyll-piperidin-4-yl ⁇ -amide:
- the title compound is prepared as a light yellow solid (49 mg, 91% yield) following Scheme 3 and in analogy to Example 53 using 7-chloro-3-oxo-3,4-dihydro-2H-pyrido[3,2- b][l,4]thiazine-6-carboxylic acid (22 mg, 0.09 mmol, 1.0 eq) and l-[2-(6-methoxy- quinolin-3-ylsulfanyl)-ethyl]-piperidin-4-ylamine (30 mg, 0.09 mmol, 1.0 eq) as starting materials.
- reaction mixture is cooled down to 0 0 C before the addition of methanol (1 mL). Solvents are evaporated and the crude is taken in water (10 mL), the p ⁇ is adjusted to 10 by the addition of IN sodium hydroxide aqueous solution and the resulting aqueous layer is extracted with diclhoromethane (3 x 10 mL).
- Example 58 3-oxo-3.,4-dihvdro-2H-benzo[l,41thiazine-6-carboxylic acid ⁇ l-[2-(7- ethoxy-quinoxalin-2-yloxy)-ethyll-piperidin-4-yl ⁇ -amide: Ethyl bromide (12.8 ⁇ L, 0.17 mmol, 1.1 eq) is added at room temperature to a stirred solution of 3-oxo-3,4-dihydro-2H-benzo[l,4]thiazine-6-carboxylic acid ⁇ l-[2-(7-hydroxy- quinoxalin-2-yloxy)-ethyl]-piperidin-4-yl ⁇ -amide (75 mg, 0.16 mmol, 1.0 eq) in N, N- dimethylformamide (2 mL), followed by potassium carbonate (28.1 mg, 0.20 mmol, 1.3 eq).
- Example 59 acetic acid 3-f2- ⁇ 4-[f3-oxo-3.,4-dihvdro-2H-benzo[l,41thiazine-6- carbonyl)-aminol-piperidin-l-yl ⁇ -ethoxy)-quinoxalin-6-yl ester:
- Acetyl chloride (11.4 ⁇ L, 0.16 mmol, 1.1 eq) is added at room temperature to a stirred solution of 3-oxo-3,4-dihydro-2H-benzo[l,4]thiazine-6-carboxylic acid ⁇ l-[2-(7-hydroxy- quinoxalin-2-yloxy)-ethyl]-piperidin-4-yl ⁇ -amide (70 mg, 0.15 mmol, 1.0 eq) in N,N- dimethylformamide (2 mL), followed by triethylamine (40.7 ⁇ L, 0.29 mmol, 2.0 eq).
- Example 60 methanesulfonic acid 3-f2- ⁇ 4-[f3-oxo-3.,4-dihvdro-2H-benzo[l,41thiazine- 6-carbonyl)-aminol-piperidin-l-yl ⁇ -ethoxy)-quinoxalin-6-yl ester:
- Methanesulfonic anhydride (519 mg, 2.92 mmol, 20.0 eq) is added at 0 0 C to a stirred solution of 3-oxo-3,4-dihydro-2H-benzo[l,4]thiazine-6-carboxylic acid ⁇ l-[2-(7-hydroxy- quinoxalin-2-yloxy)-ethyl]-piperidin-4-yl ⁇ -amide (70 mg, 0.15 mmol, 1.0 eq) in N, N- dimethylformamide (2 mL), followed by triethylamine (610.4 ⁇ L, 4.38 mmol, 30.0 eq).
- Example 61 [3-( 2- ⁇ 4- ⁇ ( 3-oxo-3.,4-dihvdro-2H-benzo [1 ,41 thiazine-6-carboiryl)-aminol - piperidin-l-yl ⁇ -ethoxy)-quinoxalin-6-yloxyl-acetic acid methyl ester:
- Example 62 3-oxo-3.,4-dihvdro-2H-benzo[l,41thiazine-6-carboxylic acid ⁇ l-[2-(7- difluoromethoxy-quinoxalin-2-yloxy)-ethyll-piperidin-4-yl ⁇ -amide:
- the title compound is prepared as an off-white lyophilizated powder following Scheme 1 and in analogy to Example 1 using 2-chloro-7-methoxy-quinoxaline, [l-(2-hydroxy-3- methoxy-propyl)-piperidin-4-yl]-carbamic acid tert-butyl ester and 3-oxo-3,4-dihydro-2H- benzo[l,4]thiazine-6-carboxylic acid as starting materials.
- Example 64 3-oxo-3.,4-dihvdro-2H-benzo[l,41thiazine-6-carboxylic acid ⁇ l-[3-(2- methoxy-ethoxy)-2-(7-methoxy-quinoxalin-2-yloxy)-propyll-piperidin-4-yl ⁇ -amide:
- the title compound is prepared as a white lyophilizated powder following Scheme 1 and in analogy to Example 1 using 2-chloro-7-methoxy-quinoxaline, ⁇ l-[2-hydroxy-3-(2- methoxy-ethoxy)-propyl]-piperidin-4-yl ⁇ -carbamic acid tert-butyl ester and 3-oxo-3,4- dihydro-2H-benzo[l,4]thiazine-6-carboxylic acid as starting materials.
- Example 65 3-oxo-3.,4-dihvdro-2H-benzo[l,41thiazine-6-carboxylic acid ⁇ l-[2-(7- methoxy-quinoxalin-2-ylsulfanyl)-3-morpholin-4-yl-propyll-piperidin-4-yl ⁇ -amide:
- Epithiochlorohydrine (268 mg, 2.40 mmol, 1.0 eq) is added at room temperature to a stirred solution of piperidin-4-yl-carbamic acid tert-butyl ester (500 mg, 2.40 mmol, 1.0 eq) in 7V,iV-dimethylformamide (15 mL), followed by potassium carbonate (335 mg, 2.40 mmol, 1.0 eq). After 24 hours stirring at room temperature, solvent is evaporated and the residue is extracted with dichloromethane (3 x 20 mL) and water (20 mL).
- the title compound is prepared as a light brown lyophilizated powder following Scheme 3 and in analogy to Example 1 using 2-chloro-7-methoxy-quinoxaline, [l-(2-mercapto-3- morpholin-4-yl-propyl)-piperidin-4-yl]-carbamic acid tert-butyl ester and 3-oxo-3,4- dihydro-2H-benzo[l,4]thiazine-6-carboxylic acid as starting materials.
- the title compound is prepared as a yellow oil (135 mg, 71% yield) following Scheme 1 and in analogy to Example 1 using (Ji?,45)-4-aminol-[2-(7-methoxy-quinoxalin-2-yloxy)- ethyl]-piperidine-3-carboxylic acid ethyl ester and 3-oxo-3,4-dihydro-2H- benzo[l,4]thiazine-6-carboxylic acid as starting materials.
- Lithium aluminium hydride (1.0M solution in tetrahydrofuran, 80 ⁇ L, 0.08 mmol, 1.0 eq) is added dropwise at -10 0 C to a stirred solution of (3i?,4S)-l-[2-(7-methoxy-quinoxalin-2- yloxy)-ethyl]-4-[(3-oxo-3,4-dihydro-2H-benzo[l,4]thiazine-6-carbonyl)-amino]- piperidine-3-carboxylic acid ethyl ester (50 mg, 0.08 mmol, 1.0 eq) in tetrahydrofuran (5 mL).
- the title compound is prepared as an orange semisolid (280 mg, 87% yield) following Scheme 3 and in analogy to Example 35 using (J5',4i?)-4-amino-l-[2-(7-methoxy- quinoxalin-2-ylsulfanyl)-ethyl]-piperidine-3-carboxylic acid ethyl ester (216 mg, 0.50 mmol, 1.0 eq) and 3-oxo-3,4-dihydro-2H-benzo[l,4]thiazine-6-carboxylic acid (113 mg, 0.50 mmol, 1.0 eq) as starting material.
- the title compound is prepared as a light yellow lyophilizated powder (38 mg, 32% yield) following Scheme 3 and in analogy to Example 66 using (3S,4R)-4-amino-l-[2-(7- methoxy-quinoxalin-2-ylsulfanyl)-ethyl]-piperidine-3-carboxylic acid ethyl ester (137 mg, 0.21 mmol, 1.0 eq) as starting material.
- Example 68 T-chloro-B-oxo-B ⁇ -dihydro ⁇ H-benzon ⁇ lthiazine- ⁇ -carboxylic acid ⁇ 1- [2-f7-methoxy-3-methyl-quinoxalin-2-yloxy)-ethyll-piperidin-4-yl ⁇ -amide:
- the title compound is prepared as a light yellow lyophilizated powder following Scheme 1 and in analogy to Example 1 using 3-chloro-6-methoxy-2-methyl-quinoxaline, [l-(2- hydroxy-ethyl)-piperidin-4-yl]-carbamic acid tert-butyl ester and 7-chloro-3-oxo-3,4- dihydro-2H-benzo[l,4]thiazine-6-carboxylic acid as starting materials.
- the title compound is prepared as a light yellow lyophilizated powder following Scheme 1 and in analogy to Example 1 using 2-chloro-7-methylsulfanyl-quinoxaline, [l-(2-hydroxy- ethyl)-piperidin-4-yl]-carbamic acid tert-butyl ester and 3-oxo-3,4-dihydro-2H- benzo[l,4]thiazine-6-carboxylic acid as starting materials.
- Example 70 S-thiophen-l-yl-isoxazole-B-carboxylic acid ⁇ l-[2-f3-methoxy-quinolin-6- yloxy)-ethyll-piperidin-4-yl ⁇ -amide:
- reaction mixture is then filtered and the filtrate is concentrated to give a yellow residue that is purified by column chromatography (silica gel, eluent: petroleum ethe ⁇ ethyl acetate:triethylamine, 2:1:0.05, v/v/v) to afford 3-methoxy-quinolin-6-ylamine as a yellow solid (4.2 g, 59% yield).
- the mixture is stirred at 0 0 C for 2 hours before its addition to a vigorously stirred solution of 10% sulfuric acic (600 mL) at 85-90 0 C within 20 minutes.
- 2-Chloro-quinolin-7-ol (4.2 g, 23.4 mmol, 1.0 eq) is added at room temperature to a stirred solution of sodium methoxide in methanol (15% weight, 200 mL, 561.6 mmol, 24.0 eq) and the resulting mixture is heated under reflux for 20 hours. Solvent is removed, the residue is dissolved in water (50 mL) and neutralized with acetic acid, followed by extraction with ethyl acetate (3 x 50 mL).
- the title compound is prepared as a white lyophilizated powder following Scheme 1 and in analogy to Example 2 using 2-methoxy-quinolin-7-ol, [l-(2-hydroxy-ethyl)-piperidin-4- yl]-carbamic acid tert-butyi ester and 3-oxo-3,4-dihydro-2H-benzo[l,4]thiazine-6- carboxylic acid as starting materials.
- Example 72 7-chloro-3-oxo-3.,4-dihvdr()-2H-beiizori.,41thiaziiie-6-carboxylic acid ⁇ 1- r2-(7-cvano-quinoxalin-2-yloxy)-ethyll-piperidin-4-yl ⁇ -amide:
- the title compound is prepared as a yellow lyophilizated powder following Scheme 1 and in analogy to Example 1 using 3-chloro-quinoxaline-6-carbonitrile, [l-(2-hydroxy-ethyl)- piperidin-4-yl]-carbamic acid tert-butyi ester and 7-chloro-3-oxo-3,4-dihydro-2H- benzo[l,4]thiazine-6-carboxylic acid as starting materials.
- a mixture of 7-fluoro-6-methoxy-quinolin-3-ylamine (prepared according to procedures described in FR2862301, 830 mg, 4.3 mmol, 1.0 eq) and concentrated hydrochloric acid (12N, 3.0 g, 30.2 mmol, 7.0 eq) is stirred at 4 0 C before the addition of sodium nitrite (313 mg, 4.7 mmol, 1.1 eq) in water (24 mL). After 2 hours stirring at 4 0 C, the resulting mixture is added dropwise to a stirred solution of concentrated sulfuric acid (8.2 mL) and water (24 mL) at 90 0 C within 10 minutes.
- Example 74 7-methoxy-2-( 2- Urans-4- ⁇ ( 3-oxo-3.,4-dihvdro-2H-benzo [ 1 ,41 thiazine-6- carbonyl)-aminol-cvclohexyl ⁇ -ethoxy)-quinoline-3-carboxylic acid:
- Lithium hydroxide monohydrate (18 mg, 0.42 mmol, 1.5 eq) is added at room temperature to a stirred solution of 7-methoxy-2-(2- ⁇ tr ⁇ r ⁇ -4-[(3-oxo-3,4-dihydro-2H- benzo[ 1 ,4]thiazine-6-carbonyl)-amino]-cyclohexyl ⁇ -ethoxy)-quinoline-3-carboxylic acid methyl ester (173 mg, 0.28 mmol, 1.0 eq) in a mixture of tetrahydrofuran/water (6 mL, 2:1, v/v).
- Example 75 6-( ⁇ 1- r2-cyclopropyl-2-( 7-methoxy-q uinoxalin-2-yloxy)-ethyll -piperidin- 4-ylamino ⁇ -methyl)- ⁇ H-benzo[l,41thiazin-3-one:
- the title compound is prepared as a white lyophilizated powder following Scheme 1 and in analogy to Examples 1 and 9 using 2-chloro-7-methoxy-quinoxaline, [l-(2-cyclopropyl-2- hydroxy-ethyl)-piperidin-4-yl]-carbamic acid tert-butyl ester and 3-oxo-3,4-dihydro-2H- benzo[l,4]thiazine-6-carbaldehyde as starting materials.
- Example 76 3-oxo-3.,4-dihvdro-2H-benzo[l,41thiazine-6-carboxylic acid ⁇ l-[2-(7,8- dimethoxy-quinoxalin-2-ylsulfanyl)-ethyll-piperidin-4-yl ⁇ -amide: Preparation of 3,4-dimethoxy-2-nitro-benzoic acid:
- Bromoacetic acid (0.876 g, 6.31 mmol, 0.5 eq) is added portionwise to 3,4-dimethoxy-2- nitro-phenylamine (2.5 g, 12.61 mmol, 1.0 eq) and the mixture is stirred at 58 0 C for 16 hours. The reaction is then quenched by 25 % ammonia in water and diluted with water. The solid is filtered off and washed with 10% ammonia in water. The combined solutions are acidified by concentrated hydrochloric acid and the resulting precipitate is collected by filtration, washed with water and dried under vacuum to afford (3,4-dimethoxy-2-nitro- phenylamino)-acetic acid as a red solid (1.1 g, 34% yield).
- Example 77 3-oxo-3.,4-dihvdro-2H-benzo[l,41thiazine-6-carboxylic acid ⁇ l-[2-(4- ethoxy-6-methoxy-[l,51naphthyridin-3-yloxy)-ethyll-piperidin-4-yl ⁇ -amide:
- N-Bromosuccinimide (263 mg, 1.48 mmol, 1.3 eq) is added at 15 0 C to a stirred solution of 6-methoxy-[l,5]naphthyridin-4-ol (200 mg, 1.14 mmol, 1.0 eq) in acetic acid (3 mL). After 30 minutes stirring at 15 0 C, the reaction mixture is allowed to come at room temperature and the resulting cake is filtered, washed with acetic acid and dried to afford 3-bromo-6- methoxy-[l,5]naphthyridin-4-ol as an off-white solid (280 mg, 97% yield).
- Diethyl azodicarboxylate (1.37 g, 7.84 mmol, 2.0 eq) is added at room temperature to a stirred solution of 3-bromo-6-methoxy-[l,5]naphthyridin-4-ol (1.0 g, 3.92 mmol, 1.0 eq), benzyl alcohol (640 mg, 5.88 mmol, 1.5 eq) and triphenylphosphine (2.05 g, 7.84 mmol, 2.0 eq) in tetrahydrofuran (25 mL).
- Tris(dibenzylideneacetone)dipalladium(0) (36 mg, 0.039 mmol, 0.02 eq) is added at room temperature to a stirred solution of 8-benzyloxy-7-bromo-2-methoxy-[l,5]naphthyridine (680 mg, 1.97 mmol, 1.0 eq) in water (10 mL), and dioxane (20 mL), followed by 4,5- bis(diphenylphosphino)-9,9-dimethylxanthene (47 mg, 0.099 mmol, 0.05 eq) and a solution of potassium hydroxide (220 mg, 3.94 mmol, 2.0 eq) in water (10 mL).
- Diethyl azodicarboxylate (5.48 g, 31.46 mmol, 2.0 eq) is added at room temperature to a stirred solution of 4-benzyloxy-6-methoxy-[l,5]naphthyridin-3-ol (4.44 g, 15.73 mmol, 1.0 eq), [l-(2-hydroxy-ethyl)-piperidin-4-yl]-carbamic acid tert-butyi ester (5.76 g, 23.59 mmol, 1.5 eq) and triphenylphosphine (8.25 g, 31.46 mmol, 2.0 eq) in tetrahydrofuran (150 mL).
- the title compound is prepared as a white lyophilizated powder following Scheme 1 and in analogy to Example 1 using (l-[2-(4-hydroxy-6-methoxy-[l,5]naphthyridin-3-yloxy)- ethyl]-piperidin-4-yl ⁇ -carbamic acid tert-butyl ester and 3-oxo-3,4-dihydro-2H- benzo[l,4]thiazine-6-carboxylic acid as starting materials.
- Ethyl iodide (13 ⁇ L, 0.16 mmol, 1.0 eq) is added at room temperature to a stirred solution of 3-oxo-3,4-dihydro-2H-benzo[l,4]thiazine-6-carboxylic acid ⁇ l-[2-(4-hydroxy-6- methoxy-[l,5]naphthyridin-3-yloxy)-ethyl]-piperidin-4-yl ⁇ -amide (90 mg, 0.16 mmol, 1.0 eq) in 7V,iV-dimethylformamide (4 mL), followed by potassium carbonate (22 mg, 0.16 mmol, 1.0 eq).
- the antibacterial activity of compounds is determined by the minimal inhibitory concentration (MIC) method.
- MICs for all bacteria except pneumococci and Haemophilus influenzae are obtained by broth microdilution with cation-adjusted Mueller-Hinton broth (CAMHB; BBL), according to CLSI guidelines (National Committee for Clinical Laboratory Standards. 2003. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 5 th ed.; approved standard M7-A6.
- Microtiter plates are incubated at 35°C in ambient air for 20 to 24 h, then inspected using an illuminated microtiter plate reader fitted with a magnifying mirror (MIC 2000; Cooke Laboratory Products, Alexandria, Va).
- MIC 2000 Cooke Laboratory Products, Alexandria, Va
- Compounds of the present invention are tested against several bacteria strains comprising some Acinetobacter baumannii, Enter ococcus faecalis, Enterococcus faecium, Escherichia coli, Haemophilus influenzae, Klebsiella pneumoniae, Pseudomonas aeruginosa, Staphylococcus aureus, Staphylococcus epidermidis and Streptococcus pneumoniae,.
- the MIC values (in mg/L) for the Examples 1 to 56 are presented in Table 2.
- the other described example compounds have a MIC for Staphylococcus aureus ATCC29213 of less or equal to 8 mg/L.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2011546788A JP5662346B2 (en) | 2009-01-21 | 2010-01-21 | New bicyclic antibiotics |
AU2010206161A AU2010206161B2 (en) | 2009-01-21 | 2010-01-21 | Novel bicyclic antibiotics |
CA2750047A CA2750047A1 (en) | 2009-01-21 | 2010-01-21 | Novel bicyclic antibiotics |
CN201080012697.4A CN102361863B (en) | 2009-01-21 | 2010-01-21 | Novel bicyclic antibiotics |
EP10700583A EP2389376A1 (en) | 2009-01-21 | 2010-01-21 | Novel bicyclic antibiotics |
US13/145,323 US8716280B2 (en) | 2009-01-21 | 2010-01-21 | Bicyclic antibiotics |
HK12103836.8A HK1163098A1 (en) | 2009-01-21 | 2012-04-18 | Novel bicyclic antibiotics |
US14/216,486 US8927542B2 (en) | 2009-01-21 | 2014-03-17 | Bicyclic antibiotics |
US14/552,853 US9133219B2 (en) | 2009-01-21 | 2014-11-25 | Bicyclic antibiotics |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09151027 | 2009-01-21 | ||
EP09151027.1 | 2009-01-21 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/145,323 A-371-Of-International US8716280B2 (en) | 2009-01-21 | 2010-01-21 | Bicyclic antibiotics |
US14/216,486 Division US8927542B2 (en) | 2009-01-21 | 2014-03-17 | Bicyclic antibiotics |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2010084152A1 true WO2010084152A1 (en) | 2010-07-29 |
Family
ID=40627154
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2010/050684 WO2010084152A1 (en) | 2009-01-21 | 2010-01-21 | Novel bicyclic antibiotics |
Country Status (8)
Country | Link |
---|---|
US (3) | US8716280B2 (en) |
EP (1) | EP2389376A1 (en) |
JP (1) | JP5662346B2 (en) |
CN (1) | CN102361863B (en) |
AU (1) | AU2010206161B2 (en) |
CA (1) | CA2750047A1 (en) |
HK (1) | HK1163098A1 (en) |
WO (1) | WO2010084152A1 (en) |
Cited By (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012085857A1 (en) | 2010-12-22 | 2012-06-28 | Actelion Pharmaceuticals Ltd | 3,8-diaza-bicyclo[4.2.0]oct-3-yl amides |
WO2012171860A1 (en) * | 2011-06-17 | 2012-12-20 | Basilea Pharmaceutica Ag | Tricyclic antibiotics |
WO2013050938A1 (en) | 2011-10-04 | 2013-04-11 | Actelion Pharmaceuticals Ltd | 3,7-diazabicyclo[3.3.1]nonane and 9-oxa-3,7-diazabicyclo[3.3.1]nonane derivatives |
WO2013061080A1 (en) | 2011-10-28 | 2013-05-02 | Astex Therapeutics Limited | Anticancer pyridopyrazines via the inhibition of fgfr kinases |
WO2013061077A1 (en) | 2011-10-28 | 2013-05-02 | Astex Therapeutics Limited | New compounds |
WO2013118086A1 (en) | 2012-02-10 | 2013-08-15 | Actelion Pharmaceuticals Ltd | Process for manufacturing a naphthyridine derivative |
WO2014118186A1 (en) | 2013-01-30 | 2014-08-07 | Bayer Pharma Aktiengesellschaft | Amino-substituted isothiazoles |
WO2014178008A1 (en) | 2013-05-02 | 2014-11-06 | Actelion Pharmaceuticals Ltd | Quinolone derivatives |
US8895601B2 (en) | 2010-04-30 | 2014-11-25 | Astex Therapeutics Ltd | Pyrazolyl quinoxaline kinase inhibitors |
US9290478B2 (en) | 2010-11-29 | 2016-03-22 | Astex Therapeutics Ltd | Substituted quinoxalines as FGFR kinase inhibitors |
US9303030B2 (en) | 2012-05-30 | 2016-04-05 | Astex Therapeutics Limited | Compounds |
US9303029B2 (en) | 2011-10-28 | 2016-04-05 | Astex Therapeutics Ltd | Substituted quinoxalines as FGFR kinase inhibitors |
WO2016096631A1 (en) * | 2014-12-17 | 2016-06-23 | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. | New antibacterial compounds |
WO2016096686A1 (en) | 2014-12-17 | 2016-06-23 | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. | Antibacterial compounds having broad spectrum of activity |
US9439896B2 (en) | 2011-10-28 | 2016-09-13 | Astex Therapeutics Ltd | Quinolines as FGFR kinase modulators |
US9447098B2 (en) | 2012-05-30 | 2016-09-20 | Astex Therapeutics Ltd | Pteridines as FGFR inhibitors |
US9493426B2 (en) | 2013-04-26 | 2016-11-15 | Astex Therapeutics Limited | Quinazolinone derivatives useful as FGFR kinase modulators |
WO2017211760A1 (en) | 2016-06-08 | 2017-12-14 | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. | New antibacterial compounds |
US9902714B2 (en) | 2014-03-26 | 2018-02-27 | Astex Therapeutics Ltd | Quinoxaline derivatives useful as FGFR kinase modulators |
US10085982B2 (en) | 2014-03-26 | 2018-10-02 | Astex Therapeutics Ltd | Combinations |
US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
CN111269247A (en) * | 2020-03-04 | 2020-06-12 | 河南科技大学第一附属医院 | Preparation method of buprofezin drug molecule with escherichia coli inhibition effect |
US10736900B2 (en) | 2014-03-26 | 2020-08-11 | Astex Therapeutics Ltd | Combinations of an FGFR inhibitor and an IGF1R inhibitor |
US10898482B2 (en) | 2015-02-10 | 2021-01-26 | Astex Therapeutics Ltd | Pharmaceutical compositions comprising N-(3,5-dimethoxyphenyl)-N'-1 methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine |
US11155555B2 (en) | 2015-09-23 | 2021-10-26 | Janssen Pharmaceutica Nv | Compounds |
US11542247B2 (en) | 2015-09-23 | 2023-01-03 | Janssen Pharmaceutica Nv | Bi-heteroaryl substitute 1,4-benzodiazepines and uses thereof for the treatment of cancer |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR090844A1 (en) * | 2012-04-27 | 2014-12-10 | Actelion Pharmaceuticals Ltd | PROCESS TO MANUFACTURE DERIVATIVES OF NAFTIRIDINE |
JP6112724B2 (en) * | 2013-10-31 | 2017-04-12 | 日本化薬株式会社 | 1,5-naphthyridine derivative and insecticide comprising the same as an active ingredient |
EP3233799B1 (en) * | 2014-12-19 | 2021-05-19 | The Broad Institute, Inc. | Dopamine d2 receptor ligands |
WO2016100940A1 (en) | 2014-12-19 | 2016-06-23 | The Broad Institute, Inc. | Dopamine d2 receptor ligands |
Citations (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0293071A1 (en) | 1987-04-07 | 1988-11-30 | University Of Florida | Redox amino acids and peptides containing them |
WO1995000511A1 (en) | 1993-06-22 | 1995-01-05 | Knoll Ag | Condensed 4-aminopyridines with antirheumatic activity |
US5442065A (en) | 1993-09-09 | 1995-08-15 | Board Of Regents, The University Of Texas System | Synthesis of tetrahydroquinoline enediyne core analogs of dynemicin |
WO2002034754A2 (en) | 2000-10-26 | 2002-05-02 | Smithkline Beecham P.L.C. | Benzoxazinone derivatives, their preparation and use |
WO2002072572A1 (en) | 2001-03-13 | 2002-09-19 | Aventis Pharma S.A. | Quinolyl propyl piperidine derivatives, the preparation thereof and compositions containing same |
WO2004002992A1 (en) | 2002-06-26 | 2004-01-08 | Glaxo Group Limited | Compounds |
WO2004014871A1 (en) | 2002-08-08 | 2004-02-19 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
WO2004035569A2 (en) | 2002-10-10 | 2004-04-29 | Morphochem Aktiengesellschaft für kombinatorische Chemie | Novel compounds with antibacterial activity |
WO2004058144A2 (en) | 2002-12-18 | 2004-07-15 | Glaxo Group Limited | Antibacterial agents |
FR2862301A1 (en) | 2003-11-17 | 2005-05-20 | Aventis Pharma Sa | 3-Fluoro-quinoline compound preparation, for use as intermediate for antibacterial agents, by heating new quinoline-3-diazonium tetrafluoroborate in organic solvent |
WO2005066176A1 (en) | 2003-12-29 | 2005-07-21 | Bristol-Myers Squibb Company | Pyrrolotriazine compounds as kinase inhibitors |
WO2006002047A2 (en) | 2004-06-15 | 2006-01-05 | Glaxo Group Limited | Antibacterial agents |
WO2006004949A1 (en) | 2004-06-30 | 2006-01-12 | Applera Corporation | Compositions and methods for detecting and quantitating polynucleotide sequences |
WO2006014580A1 (en) | 2004-07-08 | 2006-02-09 | Glaxo Group Limited | Antibacterial agents |
WO2006021448A1 (en) | 2004-08-25 | 2006-03-02 | Morphochem Aktiengesellschaft für kombinatorische Chemie | Novel compounds having an anti-bacterial activity |
WO2006032466A2 (en) | 2004-09-24 | 2006-03-30 | Actelion Pharmaceuticals Ltd | New bicyclic antibiotics |
WO2006038734A1 (en) | 2004-10-08 | 2006-04-13 | Astellas Pharma Inc. | Pyridazinone derivatives cytokines inhibitors |
WO2006099884A1 (en) | 2005-03-24 | 2006-09-28 | Actelion Percurex Ag | Beta-aminoalcohol antibiotics |
WO2006105289A1 (en) | 2005-03-31 | 2006-10-05 | Janssen Pharmaceutica N.V. | Bicyclic pyrazole compounds as antibacterial agents |
WO2007052843A1 (en) | 2005-11-04 | 2007-05-10 | Takeda Pharmaceutical Company Limited | Heterocyclic amide compound and use thereof |
WO2007086016A1 (en) | 2006-01-26 | 2007-08-02 | Actelion Pharmaceuticals Ltd | Tetrahydropyrane antibiotics |
WO2007093507A1 (en) | 2006-02-13 | 2007-08-23 | F. Hoffmann-La Roche Ag | Heterobicyclic sulfonamide derivatives for the treatment of diabetes |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS4625748B1 (en) * | 1968-07-23 | 1971-07-24 | ||
DE2359544A1 (en) | 1973-11-29 | 1975-10-30 | Hoechst Ag | CEPHEMDER DERIVATIVES AND PROCESS FOR THEIR PRODUCTION |
DE2901336A1 (en) * | 1979-01-15 | 1980-07-24 | Boehringer Mannheim Gmbh | NEW ARYLETHERS, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS |
JPS6233185A (en) * | 1985-08-06 | 1987-02-13 | Otsuka Chem Co Ltd | Novel derivative of cephalosporin compound, production thereof and pharmaceutical composition containing said derivative |
JP3137486B2 (en) | 1993-01-29 | 2001-02-19 | 松下電器産業株式会社 | Multi-screen split display device |
TW438796B (en) * | 1996-05-15 | 2001-06-07 | Hoffmann La Roche | 2,4-diaminopyrimidine derivatives, the manufacture process thereof, and the antibiotically-active pharmaceutical composition containing the same |
KR20020093965A (en) * | 2000-04-27 | 2002-12-16 | 바실리어 파마슈티카 아게 | Pyrimidinyl methyl indole derivatives with antibacterial activity |
US6602884B2 (en) | 2001-03-13 | 2003-08-05 | Aventis Pharma S.A. | Quinolylpropylpiperidine derivatives, their preparation, and compositions containing them |
DE10247233A1 (en) * | 2002-10-10 | 2004-06-17 | Morphochem AG Aktiengesellschaft für kombinatorische Chemie | New 4-substituted quinoline derivatives, useful for treating bacterial infections, optionally including additional ring nitrogens |
FR2867472B1 (en) * | 2004-03-12 | 2008-07-18 | Aventis Pharma Sa | QUINOLINE-4-SUBSTITUTED DERIVATIVES, METHODS AND PREPARATION INTERMEDIATES THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
JP4625748B2 (en) | 2005-10-13 | 2011-02-02 | 有限会社フジブルドン製作所 | Bourdon tube pressure gauge |
EP1992628A1 (en) * | 2007-05-18 | 2008-11-19 | Glaxo Group Limited | Derivatives and analogs of N-ethylquinolones and N-ethylazaquinolones |
-
2010
- 2010-01-21 CN CN201080012697.4A patent/CN102361863B/en active Active
- 2010-01-21 EP EP10700583A patent/EP2389376A1/en not_active Withdrawn
- 2010-01-21 JP JP2011546788A patent/JP5662346B2/en not_active Expired - Fee Related
- 2010-01-21 AU AU2010206161A patent/AU2010206161B2/en not_active Ceased
- 2010-01-21 US US13/145,323 patent/US8716280B2/en not_active Expired - Fee Related
- 2010-01-21 WO PCT/EP2010/050684 patent/WO2010084152A1/en active Application Filing
- 2010-01-21 CA CA2750047A patent/CA2750047A1/en not_active Abandoned
-
2012
- 2012-04-18 HK HK12103836.8A patent/HK1163098A1/en not_active IP Right Cessation
-
2014
- 2014-03-17 US US14/216,486 patent/US8927542B2/en not_active Expired - Fee Related
- 2014-11-25 US US14/552,853 patent/US9133219B2/en active Active
Patent Citations (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0293071A1 (en) | 1987-04-07 | 1988-11-30 | University Of Florida | Redox amino acids and peptides containing them |
WO1995000511A1 (en) | 1993-06-22 | 1995-01-05 | Knoll Ag | Condensed 4-aminopyridines with antirheumatic activity |
US5442065A (en) | 1993-09-09 | 1995-08-15 | Board Of Regents, The University Of Texas System | Synthesis of tetrahydroquinoline enediyne core analogs of dynemicin |
WO2002034754A2 (en) | 2000-10-26 | 2002-05-02 | Smithkline Beecham P.L.C. | Benzoxazinone derivatives, their preparation and use |
WO2002072572A1 (en) | 2001-03-13 | 2002-09-19 | Aventis Pharma S.A. | Quinolyl propyl piperidine derivatives, the preparation thereof and compositions containing same |
WO2004002992A1 (en) | 2002-06-26 | 2004-01-08 | Glaxo Group Limited | Compounds |
WO2004014871A1 (en) | 2002-08-08 | 2004-02-19 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
WO2004035569A2 (en) | 2002-10-10 | 2004-04-29 | Morphochem Aktiengesellschaft für kombinatorische Chemie | Novel compounds with antibacterial activity |
WO2004058144A2 (en) | 2002-12-18 | 2004-07-15 | Glaxo Group Limited | Antibacterial agents |
FR2862301A1 (en) | 2003-11-17 | 2005-05-20 | Aventis Pharma Sa | 3-Fluoro-quinoline compound preparation, for use as intermediate for antibacterial agents, by heating new quinoline-3-diazonium tetrafluoroborate in organic solvent |
WO2005066176A1 (en) | 2003-12-29 | 2005-07-21 | Bristol-Myers Squibb Company | Pyrrolotriazine compounds as kinase inhibitors |
WO2006002047A2 (en) | 2004-06-15 | 2006-01-05 | Glaxo Group Limited | Antibacterial agents |
WO2006004949A1 (en) | 2004-06-30 | 2006-01-12 | Applera Corporation | Compositions and methods for detecting and quantitating polynucleotide sequences |
WO2006014580A1 (en) | 2004-07-08 | 2006-02-09 | Glaxo Group Limited | Antibacterial agents |
WO2006021448A1 (en) | 2004-08-25 | 2006-03-02 | Morphochem Aktiengesellschaft für kombinatorische Chemie | Novel compounds having an anti-bacterial activity |
WO2006032466A2 (en) | 2004-09-24 | 2006-03-30 | Actelion Pharmaceuticals Ltd | New bicyclic antibiotics |
WO2006038734A1 (en) | 2004-10-08 | 2006-04-13 | Astellas Pharma Inc. | Pyridazinone derivatives cytokines inhibitors |
WO2006099884A1 (en) | 2005-03-24 | 2006-09-28 | Actelion Percurex Ag | Beta-aminoalcohol antibiotics |
WO2006105289A1 (en) | 2005-03-31 | 2006-10-05 | Janssen Pharmaceutica N.V. | Bicyclic pyrazole compounds as antibacterial agents |
WO2007052843A1 (en) | 2005-11-04 | 2007-05-10 | Takeda Pharmaceutical Company Limited | Heterocyclic amide compound and use thereof |
WO2007086016A1 (en) | 2006-01-26 | 2007-08-02 | Actelion Pharmaceuticals Ltd | Tetrahydropyrane antibiotics |
WO2007093507A1 (en) | 2006-02-13 | 2007-08-23 | F. Hoffmann-La Roche Ag | Heterobicyclic sulfonamide derivatives for the treatment of diabetes |
Non-Patent Citations (8)
Title |
---|
J. ANTIBIOTICS, 2000, pages 1071 |
J. CHEM. SOC., 1949, pages 1271 |
J. MARCH; M. SMITH: "Advanced Organic Chemistry", 2001, JOHN WILEY & SONS |
J. MED. CHEM., vol. 44, 2001, pages 1758 |
J. MED. CHEM., vol. 45, 2002, pages 3130 |
O. MITSUNOBU, SYNTHESIS, 1981, pages 1 |
R.O.; M.K. HUTCHINS: "Comprehensive Organic Synthesis", vol. 8, 1991, PERGAMON PRESS, pages: 25 - 78 |
T.W. GREENE; P.G.M. WUTS: "Protective Groups in Organic Synthesis", 1999, JOHN WILEY & SONS |
Cited By (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10519137B2 (en) | 2010-04-30 | 2019-12-31 | Astex Therapeutics Ltd | Pyrazolyl quinoxaline kinase inhibitors |
US9464071B2 (en) | 2010-04-30 | 2016-10-11 | Astex Therapeutics Ltd | Pyrazolyl quinoxaline kinase inhibitors |
US9850228B2 (en) | 2010-04-30 | 2017-12-26 | Astex Therapeutics Ltd | Pyrazolyl quinoxaline kinase inhibitors |
US8895601B2 (en) | 2010-04-30 | 2014-11-25 | Astex Therapeutics Ltd | Pyrazolyl quinoxaline kinase inhibitors |
US9856236B2 (en) | 2010-11-29 | 2018-01-02 | Astex Therapeutics Ltd | Substituted quinoxalines as FGFR kinase inhibitors |
US9290478B2 (en) | 2010-11-29 | 2016-03-22 | Astex Therapeutics Ltd | Substituted quinoxalines as FGFR kinase inhibitors |
WO2012085857A1 (en) | 2010-12-22 | 2012-06-28 | Actelion Pharmaceuticals Ltd | 3,8-diaza-bicyclo[4.2.0]oct-3-yl amides |
CN103635474B (en) * | 2011-06-17 | 2016-04-27 | 巴斯利尔药物股份公司 | Three ring microbiotic |
CN103635474A (en) * | 2011-06-17 | 2014-03-12 | 巴斯利尔药物股份公司 | Tricyclic antibiotics |
WO2012171860A1 (en) * | 2011-06-17 | 2012-12-20 | Basilea Pharmaceutica Ag | Tricyclic antibiotics |
WO2013050938A1 (en) | 2011-10-04 | 2013-04-11 | Actelion Pharmaceuticals Ltd | 3,7-diazabicyclo[3.3.1]nonane and 9-oxa-3,7-diazabicyclo[3.3.1]nonane derivatives |
US9309241B2 (en) | 2011-10-28 | 2016-04-12 | Astex Therapeutics Ltd | Naphthyridine derivative compounds |
US9527844B2 (en) | 2011-10-28 | 2016-12-27 | Astex Therapeutics Limited | Naphthyridine derivative compounds |
US9757364B2 (en) | 2011-10-28 | 2017-09-12 | Astex Therapeutics Ltd | Naphthyridine derivative compounds |
US10039759B2 (en) | 2011-10-28 | 2018-08-07 | Astex Therapeutics Ltd | Quinolines as FGFR kinase modulators |
US9303029B2 (en) | 2011-10-28 | 2016-04-05 | Astex Therapeutics Ltd | Substituted quinoxalines as FGFR kinase inhibitors |
US10052320B2 (en) | 2011-10-28 | 2018-08-21 | Astex Therapeutics Ltd | Substituted quinoxalines as FGFR kinase inhibitors |
US9309242B2 (en) | 2011-10-28 | 2016-04-12 | Astex Therapeutics Ltd | Substituted pyrido[2,3-b]pyrazines as FGFR kinase inhibitors |
US10045982B2 (en) | 2011-10-28 | 2018-08-14 | Astex Therapeutics Ltd | Substituted pyrido[2,3-b]pyrazines as FGFR kinase inhibitors |
WO2013061077A1 (en) | 2011-10-28 | 2013-05-02 | Astex Therapeutics Limited | New compounds |
WO2013061080A1 (en) | 2011-10-28 | 2013-05-02 | Astex Therapeutics Limited | Anticancer pyridopyrazines via the inhibition of fgfr kinases |
US9439896B2 (en) | 2011-10-28 | 2016-09-13 | Astex Therapeutics Ltd | Quinolines as FGFR kinase modulators |
WO2013118086A1 (en) | 2012-02-10 | 2013-08-15 | Actelion Pharmaceuticals Ltd | Process for manufacturing a naphthyridine derivative |
US9127002B2 (en) | 2012-02-10 | 2015-09-08 | Actelion Pharmaceuticals Ltd | Process for manufacturing a naphthyridine derivative |
JP2015508069A (en) * | 2012-02-10 | 2015-03-16 | アクテリオン ファーマシューティカルズ リミテッドActelion Pharmaceuticals Ltd | Method for producing naphthyridine derivative |
US9737544B2 (en) | 2012-05-30 | 2017-08-22 | Astex Therapeutics Limited | Compounds |
US9303030B2 (en) | 2012-05-30 | 2016-04-05 | Astex Therapeutics Limited | Compounds |
US9447098B2 (en) | 2012-05-30 | 2016-09-20 | Astex Therapeutics Ltd | Pteridines as FGFR inhibitors |
US10272087B2 (en) | 2012-05-30 | 2019-04-30 | Astex Therapeutics Ltd | Pteridines as FGFR inhibitors |
WO2014118186A1 (en) | 2013-01-30 | 2014-08-07 | Bayer Pharma Aktiengesellschaft | Amino-substituted isothiazoles |
US9493426B2 (en) | 2013-04-26 | 2016-11-15 | Astex Therapeutics Limited | Quinazolinone derivatives useful as FGFR kinase modulators |
CN105189520B (en) * | 2013-05-02 | 2017-10-10 | 埃科特莱茵药品有限公司 | Carbostyril derivative |
US9540399B2 (en) | 2013-05-02 | 2017-01-10 | Actelion Pharmaceuticals Ltd. | Quinolone derivatives |
CN105189520A (en) * | 2013-05-02 | 2015-12-23 | 埃科特莱茵药品有限公司 | Quinolone derivatives |
WO2014178008A1 (en) | 2013-05-02 | 2014-11-06 | Actelion Pharmaceuticals Ltd | Quinolone derivatives |
US10716787B2 (en) | 2014-03-26 | 2020-07-21 | Astex Therapeutics Ltd | Combinations |
US9902714B2 (en) | 2014-03-26 | 2018-02-27 | Astex Therapeutics Ltd | Quinoxaline derivatives useful as FGFR kinase modulators |
US10736900B2 (en) | 2014-03-26 | 2020-08-11 | Astex Therapeutics Ltd | Combinations of an FGFR inhibitor and an IGF1R inhibitor |
US10085982B2 (en) | 2014-03-26 | 2018-10-02 | Astex Therapeutics Ltd | Combinations |
US11918576B2 (en) | 2014-03-26 | 2024-03-05 | Astex Therapeutics Ltd | Combination of an FGFR inhibitor and a CMET inhibitor |
US10421747B2 (en) | 2014-03-26 | 2019-09-24 | Astex Therapeutics Ltd | Quinoxaline derivatives useful as FGFR kinase modulators |
WO2016096631A1 (en) * | 2014-12-17 | 2016-06-23 | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. | New antibacterial compounds |
US10369130B2 (en) | 2014-12-17 | 2019-08-06 | AZIEN DE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A. | Antibacterial compounds |
EA032384B1 (en) * | 2014-12-17 | 2019-05-31 | Ацьенде Кимике Рьюните Анджелини Франческо А.К.Р.А.Ф. С.П.А. | Antibacterial compounds having broad spectrum of activity |
WO2016096686A1 (en) | 2014-12-17 | 2016-06-23 | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. | Antibacterial compounds having broad spectrum of activity |
US10221144B2 (en) | 2014-12-17 | 2019-03-05 | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. | Antibacterial compounds having broad spectrum of activity |
US11684620B2 (en) | 2015-02-10 | 2023-06-27 | Astex Therapeutics Ltd | Pharmaceutical compositions comprising N-(3,5-dimethoxyphenyl)-N′-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine |
US10898482B2 (en) | 2015-02-10 | 2021-01-26 | Astex Therapeutics Ltd | Pharmaceutical compositions comprising N-(3,5-dimethoxyphenyl)-N'-1 methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine |
US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
US11155555B2 (en) | 2015-09-23 | 2021-10-26 | Janssen Pharmaceutica Nv | Compounds |
US11542247B2 (en) | 2015-09-23 | 2023-01-03 | Janssen Pharmaceutica Nv | Bi-heteroaryl substitute 1,4-benzodiazepines and uses thereof for the treatment of cancer |
US10633366B2 (en) | 2016-06-08 | 2020-04-28 | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. | Antibacterial compounds |
US10640488B2 (en) | 2016-06-08 | 2020-05-05 | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. | Antibacterial compounds |
WO2017211759A1 (en) | 2016-06-08 | 2017-12-14 | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. | New antibacterial compounds |
WO2017211760A1 (en) | 2016-06-08 | 2017-12-14 | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. | New antibacterial compounds |
CN111269247A (en) * | 2020-03-04 | 2020-06-12 | 河南科技大学第一附属医院 | Preparation method of buprofezin drug molecule with escherichia coli inhibition effect |
CN111269247B (en) * | 2020-03-04 | 2020-11-24 | 河南科技大学第一附属医院 | Preparation method of buprofezin drug molecule with escherichia coli inhibition effect |
Also Published As
Publication number | Publication date |
---|---|
CN102361863A (en) | 2012-02-22 |
AU2010206161A1 (en) | 2011-08-18 |
CA2750047A1 (en) | 2010-07-29 |
CN102361863B (en) | 2014-12-03 |
AU2010206161B2 (en) | 2014-08-07 |
JP2012515745A (en) | 2012-07-12 |
US20150080373A1 (en) | 2015-03-19 |
US8716280B2 (en) | 2014-05-06 |
US20140221348A1 (en) | 2014-08-07 |
JP5662346B2 (en) | 2015-01-28 |
EP2389376A1 (en) | 2011-11-30 |
HK1163098A1 (en) | 2012-09-07 |
US9133219B2 (en) | 2015-09-15 |
US20120040957A1 (en) | 2012-02-16 |
US8927542B2 (en) | 2015-01-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9133219B2 (en) | Bicyclic antibiotics | |
EP2167494B1 (en) | 3-amino-6-(1-amino-ethyl)-tetrahydropyran derivatives | |
EP2321307B1 (en) | Tricyclic alkylaminomethyloxazolidinone derivatives | |
WO2010041219A1 (en) | 2-benzothiophenyl-and 2-naphthyl-0xaz0lidin0nes and their azaisostere analogues as antibacterial agents | |
US9120822B2 (en) | Tricyclic antibiotics | |
ES2376488T3 (en) | TETRAHYDROPIRAN ANTIBIOTICS. | |
EP2721034B1 (en) | N-heterotricyclic antibiotics |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201080012697.4 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10700583 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2750047 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011546788 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010206161 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13145323 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010700583 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2010206161 Country of ref document: AU Date of ref document: 20100121 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 5934/CHENP/2011 Country of ref document: IN |